

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 48/00, C12N 15/63</b>		<b>A1</b>	(11) International Publication Number: <b>WO 98/52615</b>
			(43) International Publication Date: 26 November 1998 (26.11.98)

(21) International Application Number: PCT/US98/10381	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 22 May 1998 (22.05.98)	
(30) Priority Data: 60/047,426 22 May 1997 (22.05.97) US	
(71) Applicant (for all designated States except US): UAB RESEARCH FOUNDATION [US/US]; 1120G Administrative Building, 701 20th Street South, Birmingham, AL 35294-0111 (US).	
(72) Inventors; and	Published
(75) Inventors/Applicants (for US only): MOUNTZ, John, D. [US/US]; 2800 Vestavia Forest Place, Birmingham, AL 35216 (US). CURIEL, David, T. [US/US]; 824 Lindwood Road, Birmingham, AL 35222 (US). ZHANG, Huang-Ge [US/US]; 3240 Tyrol Road, Birmingham, AL 35216 (US).	With international search report. With amended claims and statement.
(74) Agents: COGEN, Ellen, S. et al.; Gifford, Krass, Groh, Sprinkle, Patmore, Anderson & Cikowski, P.C., Suite 400, 280 N. Old Woodward, Birmingham, MI 48009 (US).	

(54) Title: CONTROLLING IMMUNE RESPONSE TO SPECIFIC ANTIGENS

(57) Abstract

One major problem with adenovirus gene therapy has been the T-cell mediated immune response elicited by inoculation of adenovirus, which leads to rapid clearance of the virus and loss of transgene expression. In the instant invention, the immune response to a virus is prevented by pre-treatment with adenovirus, adenoassociated virus or herpes virus infected antigen-presenting cell (APC) expressing Fas ligand with induced T-cell tolerance. Administration of AdCMVLacZ after tolerance resulted in prolonged expression of LacZ in tolerized animals compared to control treated animals. In control, but not tolerized animals, there was proliferation of CD3<sup>+</sup> T-cell in the spleen in response to AdCMVLacZ treatment. Tolerance induction is also indicated by decreased production of interferon- $\gamma$  and IL-2 by peripheral T-cells isolated from treated animals after stimulation with the adenovirus infected APCs. T-cell tolerance is specific for the virus as the T-cell responses to an irrelative virus, mouse cytomegalovirus (MCMV) remained unimpaired. The instant invention utilizes virus specific T-cell tolerance, which is induced by APCs that co-express Fas ligand and virus antigens. The instant invention involves novel vectors and methods to induce tolerance to a viral vector gene therapy and prolong expression of a transgene in a viral host.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## **CONTROLLING IMMUNE RESPONSE TO SPECIFIC ANTIGENS**

### **Field of the Invention**

This invention relates generally to gene therapy. More specifically, the invention relates to suppressing immune system response to antigens expressed 5 on an infected host cell.

### **Background of the Invention**

The proper function of the immune system of an organism is to attack and neutralize materials which are perceived as being foreign to that organism. T-cells are one component of the immune system. T-cells can become activated to 10 specific antigens, and function to directly destroy materials which display that antigen, and they also function to sensitize other components of the immune system to the presence of that antigen. While a properly functioning immune system is vital to the health of an organism, in some instances there is a need for the selective inhibition of an immune response to particular materials.

15 For example, viral vectors, such as adenovirus, are employed in genetic therapies to introduce genetic material and products into an organism. One problem encountered with the use of such viral vectors is that they can provoke an immune response in the organism. This immune response can destroy the viral vector, and those host cells which are intentionally infected by the vector, as well 20 as therapeutic gene products produced by the action of the vector. Furthermore, immune system "memory" provides a lasting response to this vector; hence, readministration of the material will be ineffective. Therefore, there is a need for

a method whereby the immune response to a selected viral vector may be blocked or destroyed. Suppression of immune response is also desirable in the instances of autoimmune disease. As is known, such disease results when the immune system of an organism inappropriately recognizes an organ or tissue of that 5 organism as being foreign, and commences an immune response against it. If this immune response can be blocked, the autoimmune disease can be controlled. Immune suppression is also needed in those instances where organs are transplanted. Immune system suppressing drugs are sometimes employed in the foregoing situations; however, such drugs produce a generalized suppression of 10 the immune system, which leaves a patient open to a number of infections. It would therefore be advantageous if immune response to a specific antigen could be suppressed and/or an immune suppressed zone of tissue created within an organism.

Gene therapy is limited by induction of an immune response to the virus 15 or the gene-therapy protein product (1-4). A specific T-cell response to the viral vector usually results the failure of re-expression of transgene (5-6). Many efforts have been made to reduce the T-cell response to the viral vector during gene therapy, including the blockade of MHC class I and II antigen, reduce the antigenicity of the viral vector, and prevention of co-stimulation of T-cells (1,7- 20 11).

One important mechanism for maintaining peripheral T-cell tolerance is clonal deletion of antigen-specific T-cells, which is mediated by apoptosis (12-

15). Cytokine and cytokine ligand mediated apoptosis has been shown to be an important pathway for activation-induced cell death in T-cells (16-17). T-cell activation leads to upregulation of cytokine ligand and cytokine apoptosis signaling (18,19). Activated macrophages express increased levels of cytokine ligand and mediate apoptosis in the T-cells during antigen presentation, which has been thought to be a critical mean of down-modulating T-cell response (20,21).

5                   In particular, the efficiency of adenovirus-mediated gene transfer has been found to be far superior to other methods for the treatment of heart, lung, and liver disease, and is capable of producing more recombinant protein (22,23). However, 10               the cell-mediated immune response to E1a-E3-deleted adenoviral (Ad5) vector and the limited distribution of reporter gene expression suggest that less immunogenic recombinant vectors and more homogeneous administration methods are required before Ad5 vectors can be used successfully for phenotypic modulation. Neonatal intrathymic injection of the vector was able to induce long-term LacZ expression for more than 2 months after heart injection, although 15               neutralizing as well as anti- $\beta$ -Gal antibodies were detected in the sera of the animals (24). Pretreatment with the anti-TCR monoclonal antibody (mAb) H57 resulted in a significant reduction in lymphocytic infiltration and a prolongation of transgene expression (25). Studies with adenoviral vectors show that immune 20               responses limit the efficacy and persistence of gene expression. HSVtk/ganciclovir therapy was more effective in nude rats and immunosuppressed Fischer rats than in immunocompetent Fischer rats (26). The

immune response against adenovirally transduced cells limits the efficacy of the HSVtk/ganciclovir system and that immunosuppression appears to be a useful adjunct. Adenoviral transgene expression was transient in the thymus of immunocompetent mice but persistent in CD8<sup>+</sup> T-cell-deficient and severe 5 combined immunodeficiency (SCID) mice, implicating a role for cytotoxic T lymphocytes in viral clearance (27). Intrathymic transplantation of syngeneic pancreatic islet cells infected with adenovirus impaired the normal antiviral cytotoxic T-lymphocyte response and prolonged hepatic transgene expression after an intravenous challenge with adenovirus.

10 Ad5 vector expressing the lacZ transgene, upon delivery intra-articularly (5 x 10<sup>8</sup> p.f.u.), lacZ expression was observed in the articular synovium for at least 14 days. Anti-T-cell mAbs may be useful in inhibiting this immune response. Improved cell lines allow propagation of Ad with less genetic material, which decreases the antigenicity (28). The biologic efficacy and safety profile of second- 15 generation adenovirus for CFTR gene was evaluated after transfer to baboon lung. This second-generation virus is deleted of E1 and contains a temperature-sensitive mutation in the E2a gene, which encodes a defective DNA-binding protein. Using a second-generation adenovirus, recombinant gene stability was prolonged and associated with a diminished level of perivascular inflammation as compared to 20 first-generation vectors (29). These data suggest that second-generation adenoviral vectors provide an improved gene delivery vehicle and are useful in gene therapy for diseases such as cystic fibrosis.

Previous attempts to inhibit the immune response to adenovirus vector or transgenic products have all limited the utility of transgenic therapies. One technique of pre-toleration of the adenovirus is to induce neonatal toleration (30). Intratracheal administration of E1 deleted adenovirus within three days of birth 5 resulted in transgene expression for over 6 months in cotton rats. Readministration of virus into 8 to 10 week old animals resulted in low levels of neutralizing antibodies. Later there was a T-cell response which correlated with existence of the transgene from the vector administered at birth, and also the eventual development of neutralizing antibodies (30). Neonatal administration of 10 E1 deleted adenovirus to the small intestines also prolonged gene expression and decreased inflammatory response. Other investigators have used oral tolerance in rats to prolong gene expression and enable repeated injections lasting 100 days along with markedly inhibited lymphocyte response (31). The present invention for tolerance induction has the advantage that it does not require neonatal 15 administration of the adenovirus.

Another mechanism of tolerance is the use of immune privileged sites. This tolerance makes use of the natural occurrence of immune privileged sites which has more recently been thought to be due to production of Fas ligand in subsequent killing of T-cells that may develop and react with antigens within these 20 sites. Installation of adenovirus into these sites results in tolerance to adenovirus and its transgene product. This has been tested using E1 deleted adenovirus injected into this subretinal space which resulted in minimal cellular and humeral

immune response (32). The pancreatic islet may also be an immune privileged sites since murine pancreatic islets injected ex-vivo with Ad5 resulted in high level of beta galactosidase for at least 20 weeks after re-implantation (33). Adenovirus mediated gene transfer in adult mouse islets does not impair insulin secretion by the islets (34). Ad lacZ injected subretinally resulted in prolonged gene expression, which was equivalent to that observed in either nude mice or after treatment with CTLA4Ig (8). The present invention is more widely applicable since transgene expression is not restricted to immune privileged sites.

#### Summary of the Invention

10 In the instant invention antigen presenting cells (APCs) that express apoptosis inducing ligands and processed viral vector antigens are utilized to directly induce apoptosis of T-cells expressing the ligand receptor resulting in vector-specific T-cell tolerance. High levels of ligand and vector antigens are induced in APCs by co-infection. In the case of Fas ligand (FasL) as the cytokine and adenovirus vector co-infection with AdLoxpFasL+AxCANCre, pre-treatment of recipient mice with the adenovirus-infected APCs that express Fas ligand resulted in induction of T-cell tolerance to the adenovirus. The decreased T-cell response to the viral vector is demonstrated by decreased cytokine production, decreased cytotoxic T-cell response, inhibition of clonal expansion of CD3+ T-cells, and prolonged the expression of a marker transgene. Induction of T-cell tolerance to adenovirus requires expression of FasL on the APCs, and does not occur with adenovirus infected control APCs. T-cell tolerance also requires

expression of Fas on the T-cells of recipient mice, since lpr/lpr mice are not tolerized. The T-cell tolerance is virus antigen-specific as there is normal T-cell response to mouse cytomegalovirus (CMV) in tolerized mice. These results indicate that pre-tolerization with syngeneic APCs co-infected with AdLoxpFasL + AxCANCre is a novel immunointervention strategy for tolerance induction to adenovirus gene therapy.

The instant invention includes a method for promoting immunotolerance in a host to a gene therapy vector, including transfecting a host cell with the vector, such that the vector expresses a transgene, an antigen and a ligand. Expression of the ligand induces apoptosis in a T-cell that is raised against the antigen.

The instant invention also includes a method for creating an immune privileged site in a tissue of an organism, the method including providing a gene therapy vector encoding and capable of expressing a ligand, a transgene and an antigen and infecting cells of the tissue with the vector. The expression of the ligand in the tissue thereby induces apoptosis in T-cells raised against the ligand so as to confer specific immunity to infected cells.

The instant invention also teaches a gene therapy viral vector that includes a transgene, an apoptosis ligand gene and a gene expression control means for directing product synthesis of said transgene and said ligand gene. In addition, the use of such a vector for a gene therapy application is detailed.

The instant invention also discloses a gene therapy viral vector including a transgene, a viral vector gene that is expressed as an antigen on an infected host cell, a functional equivalent of a Fas ligand gene and a gene expression control means for directing product synthesis of said transgene and said Fas ligand gene.

5

#### **Brief Description of the Drawings**

**Figure 1. A schematic illustrating a production method of gene therapy viral vector to inhibit an immune response to viral vector antigens and methods of using the same to produce immune privileged transduced mammalian host cells.**

10

**Figure 2. Co-infection of APCs with AdLoxpFasL + AxCanCre (APC-AdFasL) results in high levels of FasL capable of inducing apoptosis of A20 target cells.** The AdLoxpFasL is infected into APCs from lpr/lpr mice with and without AxCANCre. As a comparison, the APCs are also electroporation transfected with pcDNA3FasL and stimulated with 15 lipopolysaccharide (LPS) (1 ug/ml). FasL expression is determined by ability of the transfected APCs to induce apoptosis of a 51Cr labeled, Fas sensitive cell line A20.

15

20

**Figure 3. Prolongation of transgene expression by Ad/FasL expressing APCs.** Ten-week-old C57BL/6-+/+ mice are treated with 1 x 10<sup>6</sup> of the APCs co-infected with AdLoxpFasL plus AxCANCre (APC-AdFasL) or APCs co-infected with

AdLoxpFasL plus AdCMVGFP (APC-AdControl) or PBS every 3 days for 5 doses. After induction of T-cell tolerance, mice are intravenously inoculated with 1010 Ad/LacZ. At the indicated time points, LacZ gene expression in the liver is analyzed by a quantitative assay (a) and In situ LacZ histochemical staining (b).

5 The error bars indicate the mean  $\pm$  SEM for 3 mice analyzed separately in triplicate assay.

10 **Figure 4. Induction of tolerance to adenovirus by APC-AdFasL.** Ten-week-old C57BL/6-+/+ mice are injected intravenously with 1  $\times$  10<sup>6</sup> APC-AdFasL, APC-AdControl or with PBS every 3 days for 5 doses as described above. On day 7 after the final injection, mice are challenged with AdCMVlacZ and T-cell cytotoxic response against APC + adenovirus is determined by killing of the APC cells infected with AdCMVGFP (5 pfu/cell). The percentages of viable GFP expressing APC cells are quantitated by FACS analysis. The error bars indicate the mean  $\pm$  SEM for 3 mice analyzed separately in triplicate assays.

15 **Figure 5. Decreased IFN-gamma and IL-2 induction by spleen cells from tolerized B6 +/+ mice.** 10<sup>6</sup> of the APC-AdFasL or APC-AdControl cells were transferred to B6 +/+ mice. The spleen cells were incubated for 24 hours with APCs that were uninfected, or infected with adenovirus, and irradiated. Levels of IL-2(A) and IFN- $\gamma$  (B) in the supernatant was determined by ELISA.

**Figure 6. IL-2 induction by spleen cells from tolerized B6 +/+ mice.**  $10^6$  of the APC-AdFasL or APC-AdControl cells are transferred to B6 +/+ mice. The spleen cells are incubated for 24 hours with APCs that were uninfected, or infected with adenovirus, and irradiated. Levels of IL-2 in the supernatant is determined by 5 ELISA.

**Figure 7. IFN-gamma induction by spleen cells from B6 lpr/lpr mice.**  $10^6$  of the *lpr* APC-AdFasL or APC-AdControl cells are transferred to B6-lpr/lpr mice. The spleen cells were incubated for 24 hours with APCs that are uninfected, or infected with adenovirus, and irradiated. Levels of IFN- $\gamma$  in the supernatant is 10 determined by ELISA.

**Figure 8. Ad/FasL APCs induces specific T-cell tolerance to adenovirus.** C57BL/6-+/+ mice (5 mice/group) are treated with either C57BL/6-+/+ mice (5 mice/group) are treated with APC-AdFasL or APC-AdControl (M $\phi$ -CV). Seven days later, mice are challenged *in vivo* with either AdCMVLacZ or mouse 15 cytomegalovirus (MCMV). After an additional 7 days, splenic T-cells are stimulated *in vitro* with APCs alone, or APCs infected with MCMV or

AdCMVLacZ. IL-2 production in the supernatants was determined by ELISA 48 hours later.

**Figures 9a-9e. Characterization of Fas ligand expressing APCs.** Peritoneal 5 resident macrophages from B6-lpr/lpr mice are isolated and cultured in RPMI-1640-12% FCS. After short-term culture, growing macrophages are tested for MHC and B7 expression. (a)-(c)  $1 \times 10^6$  macrophages are stained with biotin-conjugated anti-H-2D<sup>b</sup>, anti-IA<sup>b</sup> (PharMingen) or CTLA4-Ig (Dr. Linsley: Bristol-Myers Squibb), followed by FITC-conjugated streptavidin (Southern Biotechnology). 10,000 viable cells are analyzed by FACScan. (d) Macrophages 10 are transfected with a pcDNAIII expression vector (Invitrogen) containing a full length murine Fas ligand cDNA, or empty vector, using a standard DEAE-Dextran method. Transfected macrophages are selected with 0.5 mg/ml of G418 (Sigma). The selected macrophages are mixed with [<sup>51</sup>C]r-labeled, Fas ligand sensitive A20 15 cells at the indicated ratios and, after an 8 h incubation, the specific release is determined. (e) The splenic T-cells are purified from 4-wk-old MRL/MpJ-+/+ and MRL/MpJ-lpr/lpr mice (Jackson Laboratory) using a T-cell enrichment column (R&D Systems).  $5 \times 10^5$  purified T-cells are cultured with  $5 \times 10^4$   $\gamma$ -irradiated macrophages in round-bottom, 96-well plates for 5 d, and proliferation is 20 determined by adding 1 mCi of [<sup>3</sup>H]-thymidine (Amersham) 16 h prior to harvest.

**Figure 10. Induction of allogeneic T-cell tolerance by Fas ligand expressing APCs.** 4-wk-old of MRL-+/+ and -lpr/lpr mice are injected i.v. with macrophages ( $2 \times 10^5$ ) transfected with Fas ligand or control vector every 3 d for 6 times. On d 3 of the final injection, splenic T-cells are isolated from treated mice and cultured under various stimulatory conditions. a,  $5 \times 10^5$  T-cells are cultured with  $2 \times 10^5$   $\gamma$ -irradiated total spleen cells from B6 +/+ mice. b,  $5 \times 10^5$  T-cells are cultured with  $2 \times 10^5$   $\gamma$ -irradiated total spleen cells from BALB/c mice. c,  $5 \times 10^5$  T-cells are cultured with 5 mg/ml of anti-CD3 antibody. T-cell proliferation is determined by incorporation of [<sup>3</sup>H]-thymidine at indicated time points. The error bars indicate the mean  $\pm$  SEM for 3 mice analyzed separately in triplicate assays.

**Figure 11. Antigen-specific clonal deletion of the T-cells induced by Fas ligand expressing APCs in H-2D<sup>b</sup>/HY reactive TCR transgenic mice.** (a) Expression of H-2D<sup>b</sup> is determined as described above and analyzed by flow cytometric analysis. (b) Fas ligand activity is assayed by specific lysis of A20 target cells at the indicated E/T ratio as described in Figure 9. (c) The CD4 CD8 T-cells ( $2 \times 10^6$ ) from B6-lpr/lpr female or male mice are injected every 3 d for 3 times into female, TCR transgenic D<sup>b</sup>/HY -+/+ and -lpr mice. To demonstrate the requirement for FAS ligand in induction of T-cell tolerance, identical tolerizing experiments are carried out by co-injection with 100 mg of purified mouse Fas-Ig fusion protein capable of neutralizing Fas ligand in vivo. At the end of 12 d,  $5 \times 10^5$  spleen T-cells are stimulated with 5 mg/ml of anti-CD3 or anti-clonotypic

monoclonal antibody (M33), or with  $2 \times 10^5$  irradiated H-2D<sup>b</sup>/HY stimulator cells. The error bars indicate the mean  $\pm$  SEM for 3 mice analyzed separately in triplicate assays.

**Figure 12. Tolerance induction due to Fas-mediated deletion of M33<sup>+</sup>CD8<sup>+</sup>**

5 T-cells. (a) Expression of M33, CD8, and Fas on the T-cells in the PLN is determined by 3-color flow cytometric analysis.  $1 \times 10^6$  total PLN cells are stained with biotin-conjugated M33, then with FITC-conjugated anti-CD8 and PE-conjugated anti-Fas (PharMingen). 10,000 viable lymphocytes were analyzed by FACScan. Two-color contour plots of CD8 and M33 are shown, and the percentage of M33<sup>+</sup>CD8<sup>+</sup> T-cells multiplied by the total number of spleen cells.

10 The error bars indicate the mean  $\pm$  SEM for 3 mice analyzed. (c) Fas expression on the M33<sup>+</sup>CD8<sup>+</sup> cells. The M33<sup>+</sup>CD8<sup>+</sup> cells are gated and the histograms of Fas are shown. The percentage of Fas expression on the gated M33<sup>+</sup>CD8<sup>+</sup> T-cells is indicated.

15 **Figure 13. Fas ligand expressing  $\beta$  islet cells induce specific T-cell tolerance.**

(a) NIT-1 cells are transfected with pcDNAIII vector containing Fas ligand gene (NIT-1/FL) or empty vector (NIT-1/Ctl), and selected with G418. Fas ligand activity is measured by a [<sup>51</sup>Cr] release assay. (b) 6-wk-old female NOD mice are i.p. injected with  $5 \times 10^5$  NIT-1/FL or NIT-1/Ctl once. Splenic T-cells are isolated

20 2 wk later and co-cultured with irradiated NIT-1 cells. Proliferative T-cell

response is determined by [<sup>3</sup>H]-thymidine incorporation after 72 h culture. (c) The splenic T-cells from Example 25 are incubated with [<sup>51</sup>Cr]-labeled NIT-1 cells at indicated E/T ratios, specific release is determined at 12 h.

**Figure 14. Histologic Analysis of Insulitis.** 6 wk-old female NOD mice are i.p. 5 injected with 5 x 10<sup>5</sup> NIT-1/Ctl (A) or NIT-1/FL (B). Mice are sacrificed at 12 week of age. H&E stained paraffin sections of pancreas were examined (400x).

**Figure 15. Prolonged expression of Ad/Luc in muscle co-transfected with pFasL.** Tongue muscle of mice (5 mice/group) were analyzed at different time 10 points for luciferase production. There was increased production of luciferase in muscle cells injected with adenovirus plus FasL compared to muscle injected with adenovirus and control empty vector.

**Figure 16. Construction of pΔE1sp1b/FL and PJM17.** Production of 15 pΔE1sp1b/FasL. Shown is a 10.5 kb vector that contains Ad from 0 map units to 1 map unit, the CMV promoter, full length Fas ligand and a 0.4 kb SV40 polyA tail. This shuttle vector was combined with the 40.3 kb pJM17 vector containing the adenovirus genome -ΔE1 and also contains an origin replication and an ampicillan-resistant site.

Figure 17. Production of pΔE1sp1Bloxp/FasL. A 10.4 kb shuttle vector containing the fragment of adenovirus from 0 map unit to 1 map unit is followed by the 0.7 kb CMV promoter. This is followed by 2 LOXP sites separated by a 2 kb stuffer fragment plus a 0.3 kb bovine growth hormone polyA tail. The full-length 0.9 kb Fas ligand is cloned downstream from the stuffer fragment which is followed by an SV40 PolyA tail and by the 9.8 - 16.1 map units of adenovirus.

#### Detailed Description of the Invention

Vectors and methods are provided for introducing a transgene into a host using a virus-based delivery system, the vectors and methods designed to inhibit the host immune system from interfering with the specific gene therapy vector. The present invention incorporates the production of apoptosis inducing ligands into antigen presenting cells through gene therapy. Normally, a host T-cell directed towards an antigen of a transfected cell encounter an antigen resulting in elimination of expression of the transfecting transgene. The present invention promotes immunotolerance towards transfected host cells. As referred to herein, the term "gene" or "transgene" is a nucleic acid, either naturally occurring or synthetic which encodes a polypeptide product. The term "nucleic acid" is intended to mean natural or synthetic linear, circular and sequential arrays of nucleotides and nucleosides, e.g. cDNA, genomic DNA, mRNA, and RNA, oligonucleotides, oligonucleosides, and derivatives thereof.

An apoptosis ligand is any polypeptide cytokine that induces apoptosis or otherwise is lethal to a cell upon complexing the ligand. Hereafter, the present invention is detailed with the exemplary naturally occurring ligand, Fas ligand; however, it is appreciated that other known apoptosis ligands are similarly operative. Other such ligands illustratively include: Fas ligand 2 which induces apoptosis by acting with death domain region molecules DR3, DR4 and DR5; TNF which induces apoptosis by acting with TNFRI; Granzyme B and porferin which are natural killing molecules associated with T-cells; and antibodies specific to T-cell apoptosis ligand receptors: anti-Fas, anti-DR3, anti-DR4, anti-DR5 and anti-TNFR1.

Figure 1 is a schematic illustrating a production method of gene therapy viral vector to inhibit an immune response to viral vector antigens and methods of using the same to produce immune privileged transduced mammalian host cells. The method of producing an immune tolerated gene therapy vector of the present invention involves a series of steps. In selecting a virus to be modified by way of the present invention one examines a series of factors including: viral vector tropism, sites of vector expression within a host cell, ease of vector gene manipulation, required duration of expression, pathogenicity and the like. The adenovirus (Ad) affords many advantages as a vector as evidenced by its popularity. Ad replicates episomally within a host cell and as such the host cell genome is unaltered resulting in no transgene expression in host cell daughters. The adeno-associated virus (AAV) is a smaller virus than Ad, which is capable of

integrating into a host cells chromosomes, thereby affords the option of long-term expression. The herpes virus (HV) is trophic for the nervous system of a host and affords the option of transducing cells of the nervous system.

Upon selection of a virus, the upstream regulatory region (URR) of the 5 virus is excised. A URR contains at least a promoter which may be regulatable, for example, by TCN or steroids, or inducible, such as in Loxp/Cre system. The URR is closed into a shuttle vector plasmid. The shuttle vector contains an origin of replication, and an apoptosis ligand gene expression cassette. Optionally, a marker gene, an enhancer, a signal sequence, or a stuffer fragment are included in 10 the plasmid.

An apoptosis ligand gene or fragment thereof is excised from a source cell line and cloned into an apoptosis ligand gene expression cassette. The cassette contains control elements necessary for replication within a host cell such as a promoter, a 5' untranslated region and a polyadenylation sequence. The cassette 15 is incorporated into the shuttle vector plasmid so as to stimulate apoptosis ligand expression in concert with reading of the viral URR.

The shuttle vector plasmid is then combined with a viral vector replication plasmid from with the pathogenic protein encoding genes have been deleted or at least inactivated. The combined plasmids form a recombinant for delivering 20 selected portions of the viral genome and an apoptosis ligand for suppressing the immune response to transfected cells presenting viral antigens thereon. Figure 1 shows the transgene expression cassette as being incorporated into the vector

replication cassette. Alternatively the transgene expression cassette is incorporated into the shuttle vector plasmid.

The recombinant is then alternatively introduced into a cell culture or into a mammalian host. The transfection of a cell culture is carried out by a prior art method (35). The transfected cells expressing viral antigens and an apoptosis ligand are identified by methods illustratively including indirect immune fluorescent assay and  $^{51}\text{Cr}$  release assay. Preferably, the transiently transfected antigen presenting cell lines are macrophages or NIT-1  $\beta$  islet pancreas cells. It is appreciated that the present invention is readily extended to be mediated by a cell-cell interaction where the apoptosis ligand is expressed on cell type one which also expresses a different ligand, the different ligand being able to activate a receptor on a second cell type. The preferred situation is where the different ligand of cell type one - receptor of the second cell type interaction up-regulates a death domain molecule in the second cell type.

15            Cultured cells expressing both the ligand and viral vector antigens are then exposed to T-cells that have been sensitized to the viral vector. The immune system challenged transfected cells are then assayed as to proliferation, or cytotoxicity or as to the inducement anti-viral vector antibody production. These assays are designed to, alone or in combination assess the extent of immunotolerance sensitized immune system components have towards the gene therapy 20 vector.

The recombinant is introduced into a mammalian host by a route dictated by the targeted host cells. For instance, lung tissue to be transfected with CFTR or protease inhibitor so as to treat cystic fibrosis is preferably administered intra-nasally as an aerosol suspension; blood to be transfected with Factor 8 so as to treat hemophilia is preferably administered intravenously, intra peritoneally to transfect organ specific diseases of the liver, pancreas, etc., intra marrow for marrow and intra-myocardial for heart tissue. It is recognized that adjuvants are readily added to a gene therapy vector of the present invention to facilitate administration. The host transfected tissues are biopsied or excreted gene product markers associated with the gene therapy are assayed to monitor the efficacy of the therapy. *In vitro* assays are also applicable to *in vivo* therapy monitoring.

The present invention provides for a gene therapy vector capable of delivering a complete apoptosis ligand, as well as smaller functional components of these ligands. Certain truncations of these ligands interact with death domain molecules and thereby induce T-cell apoptosis. For example, the nucleic acid sequences coding for Fas ligand, Fas ligand 2, Granzyme B and porferin can be altered by substitutions, additions, deletions or multimeric expression that provide for functionally equivalent ligands. Due to the degeneracy of nucleic acid coding sequences, other sequences which encode substantially the same amino acid sequences as those of the naturally occurring ligands may be used in the practice of the present invention. These include, but are not limited to, nucleic acid sequences comprising all or portions of the nucleic acid sequences encoding the

above ligands, which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. For example, one or more amino acid residues within a sequence can be substituted by another amino acid of a similar polarity which 5 acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, 10 threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the scope of the present invention are ligands or fragments or derivatives thereof which are differentially modified during or after translation, e.g., by glycosylation, 15 protolytic cleavage, linkage to an antibody molecule or other cellular ligands, etc. In addition, the recombinant ligand encoding nucleic acid sequences of the present invention may be engineered so as to modify processing or expression of a ligand. For example, a signal sequence may be inserted upstream of a ligand encoding sequence to permit secretion of the ligand and thereby facilitate apoptosis.

20            Additionally, a ligand encoding nucleic acid sequence can be mutated *in vitro* or *in vivo* to create and/or destroy translation, initiation, and/or termination sequences or to create variations in coding regions and/or form new restriction

endonuclease sites or destroy pre-existing ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to *in vitro* site directed mutagenesis (36), use of Tab linkers (Pharmacea), etc.

5           In the case of the Fas ligand, polymorphisms in the intracellular domain modify the hydrophilic regions of the ligand but do not greatly affect Fas ligand function in inducing apoptosis. Thus, mutations of Fas ligand that do not affect the apoptosis inducing potential of the ligand including additions, substitutions, truncations and the like are recognized to be usable in the present invention.

10          Indeed, a polynucleotide modification of Fas ligand to produce multimers of the Fas ligand is a means of increasing apoptosis potential of the Fas ligand. By extension, the same holds true for other ligands. It is known to the art that soluble Fas ligand binds to Fas and may impede apoptosis by endocytosis of Fas without inducing apoptosis. Therefore, larger conglomerates of Fas ligand such as surface

15          Fas ligand or Fas ligand that has been engineered to be cross-lined and produced by cells is more affective in the induction of apoptosis than the naturally occurring Fas ligand.

              In accord with the present invention, T-cells which are activated against a specific antigen, are selectively eliminated thereby preventing or reducing

20          immune response to that antigen. T-cells are eliminated by activation-induced cell death of T-cells, which is caused by Fas-mediated apoptosis of those activated T-cells that express Fas and Fas ligand.

In the immune system, macrophages and other specialized cells, collectively referred to as antigen presenting cells (APCs), ingest antigen materials and break them into smaller peptide fragments which are presented on the surface of the APCs as a complex with major histocompatibility complex (MHC) molecules. A particular peptide/MHC complex is recognized by the specialized receptor on the surface of a T-cell thereby activating that T-cell. Activated T-cells then reproduce, and the offspring proceed to initiate an immune response by attacking those materials displaying the foreign antigen, and by further activating B cells and other components of the immune system. In addition, some of the activated T-cells persist so as to provide an enhanced response to further infection.

10 In accord with the present invention, it has been found that immune response to a specific antigen can be very effectively blocked, if the activated T-cells, responsive to that antigen, are eliminated.

It has further been found in accord with the present invention that the Fas ligand can be employed to produce apoptosis of T-cells that express Fas. More specifically, it has been found that introduction of APCs, that express a Fas ligand, into an organism will induce apoptosis of T-cells that express Fas, thereby resulting in antigen specific T-cell tolerance. It has been found that an adenovirus capable of expressing the Fas ligand can be used to transfect macrophages and other APCs. This results in a highly efficient presentation of adenovirus antigens and Fas ligand on the APCs. Such APCs will then confer immune tolerance to the adenovirus vector by selectively eliminating those T-cells which are capable of

reacting with antigens from the adenovirus vector. This novel therapeutic approach greatly enhances the utility of adenoviral based gene therapies by producing specific tolerance to the therapeutic materials. Since the therapy of the present invention is highly selective, adverse affects heretofore encountered with 5 broad immunosuppressive approaches are eliminated.

It has further been found that adenovirus, expressing the Fas ligand, can be targeted to APCs via the mannose receptors on the APCs. APCs can be transfected with Fas, *in vitro*, and the transfected cells introduced into the organism; or, transfection may occur *in vivo*, by administration of the adenovirus 10 vector to the organism.

Principles of the present invention are also be employed to inhibit autoimmune responses. As is known, autoimmune disease occurs when an organism's immune system becomes activated toward tissue of the organism itself. Selective apoptosis of those activated T-cells which cause the autoimmune 15 response will control autoimmune disease. Transfection of those cells which elicit the autoimmune response with the Fas gene will produce syngeneic cells which will induce tolerance to an autoimmune antigen, in T-cells via Fas mediated apoptosis. The syngeneic cells may comprise APCs or they may comprise cells of the tissue provoking the autoimmune disease, in which instance these cells will 20 then cause the APCs to present the Fas ligand and the autoimmune antigen.

These principles are also be employed to produce immune privileged sites within an organism. Provision of an immune privileged site facilitates organ

transplant and other such tissue graft procedures. An immune privileged site also prolongs expression of an adenovirus gene product at that site. Creation of the immune privileged site is accomplished by causing cells at the site to produce the Fas ligand, and the presence of this ligand will protect an adenovirus from 5 immune system attack. Production of Fas ligand is accomplished by the virus used for the therapy itself, or by genes introduced into the tissue via another carrier.

Fas ligand expression induces specific tolerance by apoptosis. Fas ligand expression is also induced by clonal deletion. Peripheral T-cell tolerance is 10 maintained by activation-induced cell death of the T-cells, which is mediated by Fas-mediated apoptosis of the activated T-cells that express Fas and Fas ligand (37-41). Thus, Fas ligand expression is used to create immune-privileged sites and prevent graft rejection by inducing apoptosis in the T-cells (42-44). Transplantation of APCs expressing Fas ligand induces apoptosis of T-cells that 15 express Fas, resulting in antigen-specific T-cell tolerance. The instant invention includes a novel immunointervention strategy for adenovirus gene therapy in which Fas ligand gene therapy is used to confer immune privilege. This response is mediated at the cell level and an immune response to cells is prevented by Fas ligand production by these cells. In one embodiment of the instant invention, the 20 mouse FasL is introduced into the E1A site of Ad to produce a recombinant virus which is both replicative defective and expresses high levels of Fas ligand. Such a transgene vector inhibits the immune response of the host thereto, resulting in

highly efficient presentation of adenovirus antigens and Fas ligand on the macrophages. This confers immune tolerance to the adenovirus gene therapy by selectively eliminating T-cells capable of reacting with adenovirus vector antigens.

The current results demonstrate that AdLoxpFasL co-infection with 5 AxCANCre results in very high levels of FasL in a majority of infected APCs. These APCs can express high levels of Fas ligand without undergoing autocrine suicide. This is in contrast to low efficiency transfection of DNA into APCs using lipofectin (1%-5%) or electroporation (8%). The present invention utilizes several unique technologies to allow high expressions of Fas ligand plus high expression 10 of process adenovirus antigen on an antigen presenting cell to induce apoptosis of T-cells that react with this antigen.

The present invention demonstrates extremely efficient inhibition of CD3<sup>+</sup> T-cell expansion that are potentially reactive with APC processed adenovirus antigens leading to prolongation of gene expression by challenge after tolerance 15 with AdCMVLacZ. High efficiency inhibition of adenovirus-reactive T-cells is achieved by first treatment of mice with 5 dosages of APC-AdFasL using APCs from B6-*lpr/lpr* mice. After administration every three days with 5 dosages, these APCs toleralize to antigens for up to four weeks by inhibition of APC/antigen reactive T-cells. Therefore, administration of AdCMVLacZ (10<sup>10</sup> pfu.) 20 intravenously one week after tolerance does not lead to a significant T-cell response since there is deletion or inhibition of all potentially reactive T-cells. One week after challenge with intravenous AdCMVLacZ, there was no visible

expansion of CD3<sup>+</sup> T-cells in the spleen. The absence of cytotoxic T-cells at 7 days post-infection with AdCMVLacZ correlates with a prolonged expression of LacZ in tolerized mice compared to non-tolerized mice. The present invention shows that adenovirus expression Fas ligand within an antigen presenting cell used as pretreatment can be utilized to tolerize against second administration of adenovirus/gene therapy product.

Mice are tolerized with APC-AdFas-L. There are several independently novel features to the inventive tolerance procedure. First, although direct intravenous injection of AdLoxpFasL + AxCANCre results in high co-infection of liver cells and extensive liver necrosis (45), there was no liver toxicity due to APC-Fas ligand cell therapy. Therefore, the use of APCs cell therapy results in high migration of APCs to lymphoid organs, such as the spleen, and not the liver. Second, AdCMVLacZ is used to challenge mice, but the LacZ gene is not encoded in the AdLoxpFasL + AxCANCre viruses infecting the tolerizing APCs, since this would require a triple adenovirus infection, with potentially lower infection efficiency. Nevertheless, there is tolerance to readministration of AdCMVLacZ during challenge. AdCMVLacZ elicits an immune response to LacZ as well as adenovirus (46-48). These results indicate that tolerance to adenovirus alone can prolong gene therapy even in the absence of tolerance to one of the more immunogenic transgenes, LacZ.

Tolerance induction by APCs infected with a viral vector expressing high levels of FasL is specific for the viral vector, but not with an irrelevant virus.

These results are demonstrated by tolerizing the mice with APC-AdFasL, and then challenging one week later with either AdCMVLacZ or murine cytomegalovirus (MCMV), and determining the cytotoxic response one week after challenge. There is no stimulatory response, determined by IL-2 production, after stimulation of splenic T-cells in vitro with APCs infected with AdCMVLacZ, whereas there was normal IL-2 production by T-cells from identically tolerized mice, after challenge *in vivo*, and stimulation in vitro with MCMV. This is significant since other methods for induction of tolerance, or immunosuppression to a viral vector gene therapy are associated with a more generalized immunosuppressed state, which would be undesirable for long-term gene therapy use. However, the present tolerizing technique completely abrogates the ability of responding to the tolerizing virus used to infect the APC, but not to APC infected with an irrelevant virus. Therefore, the present invention for tolerizing to a viral vector gene therapy is widely applicable, does not result in generalizing immune-suppression and is amenable to readministration for repeated treatment without inducing an immune-suppressed state.

Specific targeting of adenovirus to macrophages is accomplished by either of two methods. The first approach uses a method to couple the adenovirus fiber/knob to a mannosylated polylysine peptide. The modified receptor is targeted to macrophages. This technique is used to attach mannosylated polylysine to a modified, replicative defective adenovirus to determine adenovirus redirection to combine with high efficiency to APCs *in vivo*. These experiments

show that modified adenovirus is directed to macrophages *in vivo* and macrophage expression of Fas ligand combined with presentation of adenovirus gene products and the desired new gene product is efficacious in prolonged expression. The result is a decrease in the initial inflammatory response to the adenovirus, along 5 with induction of long-term T-cell tolerance, allowing for prolonged survival of cells expressing the adenovirus gene product, as well as decreased immunogenicity to the adenovirus and to the adenovirus gene product. Another method for APC infection with Ad involves using the adenovirus-polylysine infection technique to deliver adenovirus-polylysine-DNA complexes to 10 accompany gene therapy to targeted cells for cell lines that did not already express Fas ligand. This is advantageous in the creation of immunoprivileged sites in cells that do not express Fas ligand or do not undergo apoptosis after expressing Fas ligand. This may be especially advantageous for creating immune privileged cells 15 *in vitro* or for delivering to sites where low Fas expression occurs such as in the lung.

A more stringent test of tolerance induction involves later challenges of the mice *in vivo* with either the Ad-APC-FL or Ad-APC, as well as control Ad without APC. This subsequent reaction elicits a strong secondary immune response in the mice that were previously immunized with adenovirus, but there 20 is little or no response in mice that have been tolerized with Ad-APC-FL. The use of the Ad-APC-FL and Ad-APC, or Ad in the subsequent administration determines if Ad-APC-FL is required with each administration of adenovirus for

a specific APC, or if the initial induction of tolerance confers long-term tolerance to adenovirus. This technique is used to induce tolerance to alloantigens, and that systemic administration of APC-FL does not induce significant toxicity to the liver or long and has no other apparent toxic effect on the mouse. Thus, it may be 5 advantageous to have continued expression of FasL by the Ad infected cell to create immune privilege sites.

Fas-ligand gene therapy is useful as a strategy to prevent immune response to viral vector antigens and in this embodiment of the invention, adenovirus. The ability to exploit this strategy is supported by the finding that Fas ligand expression can be targeted to APC in vitro using the polylysine method for targeting Fas ligand and adenovirus. This method promotes targeted gene delivery via the receptor mediator endocytosis pathway (49-53). It is necessary in this approach to link the vector, such as adenovirus to molecular conjugates and, at the same time, preserve both the binding and endosome disruption capabilities of the 10 virus. Since fiber and penton proteins are believed to be primary responsible for binding and internalization, respectively, and hexon protein is thought to be a “scaffolding protein,” the conjugates are preferably linked through the hexon protein. The linkage is accomplished by an antibody bridge through a molecular conjugate and the viral vector. This is accomplished by conjugating a monoclonal 15 antibody against a foreign epitope on the viral vector hexon protein to the polylysine.

Preferably, the normal viral tropism of the vector is ablated. In the case of an adenoviral vector, redirection to macrophages optionally involves the mannosylated fiber-knob (53-57). Regulation of the macrophage mannose receptor expression and cloning of the mannose receptor has been carried out (58-60). The first three exons of the mannose receptor gene encode: a signal sequence, the NH<sub>2</sub>-terminal cysteine rich domain, and the fibronectin type II repeat, while the final exons encode the transmembrane anchor and the cytoplasmic tail. The intervening 26 exons encode the 8 carbohydrate-recognition domains and intervening spacer elements. The mannose receptor is expressed on 10 alveolar macrophages and a highly homologous receptor DEC-205 is expressed on dendritic cells and thymic epithelial cells (58). DEC-205 is able to bind carbohydrates and mediate endocytosis. It is rapidly taken up into the coated pits forming vesicles and delivered to a multi-vesicular endosomal compartment that resembles the MHC class II-containing vesicles. Thus, the mannose receptor on 15 macrophages and APCs provides an excellent target for modified adenovirus tropism and delivery of genes to APCs. The present invention preferably utilizes adenovirus expressing Fas ligand under the regulation of a well characterized target cell lysozyme promoter or a similar target specific promoter to transfect into a target cell (61-63) efficiently present of viral vector antigens and a cytokine 20 ligand on the target cells.

**Examples****Example 1 - Animals.**

Four to six week-old, female C57BL/6-+/+ and C57BL/6-*lpr/lpr* mice were obtained from the Jackson Laboratory (Bar Harbor, MA). Mice were maintained in pathogen free condition.

**Example 2 - Construct Fas ligand expression adenovirus vector.**

This is carried out as previously described (45). Briefly, a 10.4 kb shuttle vector containing the fragment of adenovirus from 0 map unit to 1 map unit followed by the 1.6 kb chicken  $\beta$ -actin promoter plus CMV enhancer. This is followed by 2 Loxp sites separated by a Neo resistant gene plus a 0.3 kb bovine growth hormone poly A tail. The full-length 0.9 kb FasL is cloned down-stream from the bovine growth hormone poly A tail which is followed by an SV40 polyA tail and by the 9.8 - 16.1 map units of adenovirus.

**Example 3 - MCMV Virus.**

MCMV Virus Smith strain is obtained from the American Type Culture Collection (Rockville, MD). The virus are titrated as duplicates in  $\log_{10}$  dilutions on subconfluent primary murine embryo fibroblasts in 12-well plates. Seven days later, monolayers are stained with neutral red and the number of plaques counted. The supernatant is dispensed into aliquots, which are stored at -80°C and used as the MCMV stock virus pool ( $3 \times 10^7$  PFU/ml).

**Example 4 - Infection of antigen presenting cells for Fas ligand expression.**

This is carried out as previously described (45). Murine B6-*lpr/lpr* APCs are infected with either AdLoxpFasL plus AxCANCre (APC-AdFasL) or AdLoxpFasL plus AdCMVGFP (APC-AdControl) at 5 pfu/cell of each viruses for 5 1 hour at 37° C, and then infected cells continue to incubated at 37° C for additional 24 hrs. Expressed murine FasL and adenoviral antigens on the surface of B6-*lpr/lpr* APCs are identified using indirect immune fluorescent assay (64) and the killing activity is evaluated by  $^{51}\text{Cr}$  release assay (65).

**10 Example 5 - Analysis of FasL by APCs Infected with AdLoxpFasL plus AxCANCre.**

Fas ligand (FasL) cytotoxicity is assayed as previously described (65). FasL expression is determined by ability of the transfected APCs to induce apoptosis of a  $^{51}\text{Cr}$  labeled, Fas sensitive cell line A20. Target cells ( $1 \times 10^6$ ), which are sensitive to cytotoxic lysis, are incubated with 20  $\mu\text{Ci}$  of  $[^{51}\text{Cr}]$ -sodium chromate in 100  $\mu\text{l}$  of RPMI-1640 containing 10% FCS at 37°C for 1 h. After 15 washing with medium, these cells are used as target cells. Effector cells are prepared from B6-*lpr/lpr* APCs infected with AdLoxpFasL plus AxCANCre as described above. These effector cells are then incubated with  $[^{51}\text{Cr}]$ -labeled target cells ( $1 \times 10^4$ ) at different effector/target (E/T) ratios in a total volume of 200  $\mu\text{l}$  of 20 the medium. Release of  $^{51}\text{Cr}$  into the supernatant is assessed 6 h later using a  $\beta$ -counter.

The percentage of specific  $^{51}\text{Cr}$  release is calculated as follows:

$$\% \text{ specific lysis} = \frac{(\text{experimental } {}^{51}\text{Cr release} - \text{spontaneous } {}^{51}\text{Cr release})}{(\text{maximum } {}^{51}\text{Cr release} - \text{spontaneous } {}^{51}\text{Cr release})}$$

5 The spontaneous release of  ${}^{51}\text{Cr}$  using these assays has routinely been 8%-12% of the maximum release.

**Example 6 - Administration of APC-AdFasL for induction of tolerance.**

10 Ten-week-old C57BL/6-+/+ mice are injected intravenously with  $1 \times 10^6$  of the APCs co-infected with AdLoxpFasL plus AxCANCre (APC-AdFasL) or APCs co-infected with AdLoxpFasL plus AdCMVGFP (APC-AdControl) or with PBS every 3 days for 5 doses. On day 7 after the final injection, mice are challenged with AdCMVlacZ and T-cell cytotoxic response against APC + adenovirus is determined one week after challenge

**Example 7 - Analysis of Immune Response to Adenovirus and MCMV after tolerance.**

15 One week after tolerance, mice are treated with AdCMVlacZ ( $1 \times 10^{10}$  pfu i.v.) or MCMV ( $1 \times 10^5$  pfu i.v.). After an additional 7 days, purified splenic T-cells are stimulated *in vitro* with APCs alone, or APCs that are incubated either with MCMV or AdCMVlacZ. After 48 hours the supernate is collected and analyzed for IL-2 and Ifn- $\gamma$  expression.

20 **Example 8 - Quantitation of  $\beta$ -galactosidase expression in liver.**

$\beta$ -galactosidase activity is determined as previously described (66).

Freshly isolated liver tissue is homogenization for 10 s in a tissumizer in 1 ml of  $\beta$ -gal buffer (Tropix, Inc., Bedford MA). The homogenate is centrifuged at 12,500 x g for 10 min at 4°C, and the supernatant is heated for 60 min at 48°C to

inactivate the endogenous eukaryotic  $\beta$ -galactosidase activity. The sample is then centrifuged at 12,500 x g for 5 min, and 10  $\mu$ l of the supernatant is assayed for  $\beta$ -galactosidase activity using the Galacto-light<sup>TM</sup> (Tropix, Inc., Bedford MA) chemi-luminescent reporter assay. The reaction is carried out for 10 min at room temperature (RT) and  $\beta$ -galactosidase activity is assayed using a luminometer (Monolight 500). The protein concentration is determined by the Bradford assay (Bio-Rad). The activity is expressed as the relative light units/min/mg of total protein in the liver.

10 **Example 9 - Analysis of Adenovirus Specific Cytotoxic T-cell Analysis Using AdCMVGFP infected Target Cells.**

The adenovirus shuttle vector construct is produced by cloning the enhanced GFP gene from pCA13 (Clonetech) into the HindIII-XbaI site. This is cotransfected with pJM17 to produce recombinant AdCMVGFP. AdCMVGFP is plaque purified by 3 rounds of selection. These are used to infect APC to be used 15 as target cells for analysis of cytotoxic effector T-cells from mice treated with APC (AdLoxpFasL+AdCMVGFP) and APC (AdLoxpFasL+AxCANCre). Effector cells are prepared from spleen, and peripheral lymph nodes of Ad-immunized and non-immunized mice. These effector cells are then incubated 20 with AdCMVGFP-infected target cells ( $1 \times 10^5$ ) at different effector/target (E/T) ratios in round-bottom microtiter plates in a total volume of 200  $\mu$ l of the medium for 48 hours, and Green fluorescent positive APC are sorted using FACS analysis. The percentage of specific cytotoxicity was calculated as follows:

$$\% \text{ specific lysis} = \frac{(100\% - \text{experimental \% GFP}^+ - \text{spontaneous \% GFP}^+)}{(100\% - \text{maximum \% GFP}^+ - \text{spontaneous \% GFP}^+)}$$

5 **Example 10 - Cytokine production in vitro in response to APC infected with adenovirus.**

B6 lpr/lpr APCs are infected with AdCMVLacZ (10 pfu/cell) for 1 hour in 1 ml of media and then diluted to additional of 10 ml of RPMI1640 supplemented with 10% fetal bovine serum. The cells continue to culture at 37°C for 24 hours. Before as a targeting cells, the APC is  $\gamma$ -irradiated, and  $1 \times 10^5$  APC 10 are mixed at different ratios of T-cells isolated from the spleen of tolerized mice. The mixed cells are incubated at 96 well plate for 2 days at 37°C. The supernatants are collected and induction of IL2 and interferon gamma are determined using ELISA assay kit (R & D systems Inc., MN).

15 **Example 11 - Histopathological examination of tissue sections.**

Animals are sacrificed by cervical dislocation. Organs were removed and fixed in neutral 10% formalin/phosphate-buffered saline for 24 hr, followed by fixation in 70% ethanol for 24 hr. Tissues are then embedded in paraffin blocks, sectioned into 10  $\mu\text{m}$  thickness, and stained with hematoxylin and eosin (H&E).

20 **Example 12 - Immunohistochemistry.**

Paraffin-embedded tissue sections are deparaffinated and treated with 3%  $\text{H}_2\text{O}_2$  at RT for 15 min. After washing 3 times with neutral phosphate buffered saline, tissues are stained with an antibody against anti-CD3 (Dako Corporation, Carpinteria, CA) following standard avidin-biotin conjugate (ABC) immunohistochemical techniques according to manufacturer's manual (Dako

Corporation, Carpinteria, CA). A peroxidase-conjugated secondary antibody is then applied to the sections at RT for 2 h. Positive staining is visualized using diaminobenzidine (DAB) substrate (Dako Corporation).

**Example 13 - Statistical analysis.**

5 The two-tailed Student's t-test is used for statistical analysis when two different groups of samples are compared. The one factor analysis of variance (ANOVA) test is used when more than two groups of samples were compared. A p value of less than 0.05 was considered significant.

10 **Example 14 - Co-infection of AdLoxpFasL + AxCANCre results in high levels of FasL capable of inducing apoptosis of A20 target cells.**

The instant invention includes an AdLoxpFasL modified adenovirus to yield high titer production of the virus in 293 cells (45). This technique also facilitates control of FasL expression since FasL is not expressed in the absence of co-infection with AxCANCre. This technique is used to induce high FasL expression by a APC cell from Fas-mutant B6-*lpr/lpr* mice which could induce apoptosis of A20 target cells (Fig. 2). There are very high lyses of the A20 target cells by APC infected with AdLoxpFasL + AxCANCre (APC-AdFasL) as FasL activity in APC-AdFasL is 10-fold higher compared with that of APCs transfected by electroporation with a pcDNAIII-FasL expression vector, and 100-fold higher compared to LPS-activated APCs (Fig. 2A). High levels of FasL expression by the APCs is sustained for at least 7 days of *in vitro* culture (Fig. 2B). There is no cytotoxicity using APC + AdLoxpFasL (APC-AdControl) alone (not shown).

**Example 15 - Prolonged Lac Z expression in the liver after tolerance with APCs/AdFasL therapy.**

Expression of adenovirus gene therapy in the liver is limited due to an acute inflammatory response and a chronic cytotoxic T-cell response (67). To 5 determine if induction of adenoviral vector specific T-cell tolerance by AdFasL expressing APCs leads to prolongation of transgene expression delivered by adenoviral vector, the APC-AdFasL tolerized and APC-AdControl treated mice are inoculated with AdCMVLacZ ( $1 \times 10^{10}$  pfu). LacZ gene expression in the liver is kinetically analyzed by quantitative measurement of LacZ protein and 10 histochemistry staining. The levels of LacZ gene expression in the liver rapidly decreased in mice treated with APC-AdControl (Fig. 3a). In contrast, in mice treated with APC-AdFasL, the levels of LacZ gene expression is not decreased and is sustained for at least 50 days after gene delivery (Fig. 3a). Histochemistry staining shows that LacZ positive cells is detectable in the liver of mice received 15 Ad/FasL expressing APCs at day 30 after delivery, whereas there were few LacZ positive cells in the liver received control treatment (Fig. 3b).

**Example 16 - Decreased cytotoxic response after FasL toleration.**

LacZ expression peaked at day 7 after expression of AdCMVLacZ in both toleralized and non-toleralized mice, and rapidly decreased in non-toleralized mice 20 compared to non-toleralized after day 7. To determine if this prolonged expression of LacZ after day 7 in the liver is associated with a decreased cytotoxic response to adenovirus, mice are toleralized *in vivo* as described above and challenged with AdCMVLacZ. Seven days after challenge splenic T-cells are

purified and used as effect cells at different E/T ratios to kill AdCMVGFP infected APCs. There is a high cytotoxic response by T-cells from mice treated with APC-AdControl after challenged with AdCMVLacZ (Figure 4). This is indicated by the increased killing of APC infected with AdCMVGFP. In contrast there was 5 low cytotoxicity of mice tolerized with APC-AdFasL or PBS and challenged with AdCMVLacZ to the AdCMVGFP infected APCs.

**Example 17 - T-cell tolerance demonstrated by decreased IFN- $\gamma$  and IL-2 production *in vivo*.**

Mice are tolerized as above with either APC-AdFasL or APC-AdControl 10 as a control. Thirty days after tolerance induction, mice are sacrificed and spleen cells are stimulated with APC or APC infected with AdCMVLacZ. Non-infected APCs did not stimulate T-cells as determined by low IL-2 (Figure 5A) and IFN- $\gamma$  (Figure 5B) in the supernate at 24 or 48 hours (Figure 4). In contrast, there is 15 high production of IL-2 and IFN- $\gamma$  from spleen cells from C57BL/6 which are tolerized with APC-AdControl, which do not express FasL. B6 $^{+/+}$  mice that are tolerized with APC-AdFasL are tolerized as indicated by low IL-2 (Figure 5A) and IFN- $\gamma$  (Figure 5B) in the supernate at 24 or 48 hours.

**Example 18 - Fas Expression by Recipient T-cells is required for tolerance Induction.**

20 Fas expression in recipient C57BL/6 mice is required for tolerance induction since spleen cells from B6-*lpr/lpr* mice produced high levels of IFN- $\gamma$  and IL-2 despite being tolerized with APC-AdFasL (Fig. 6A, 6B).

**Example 19 - Decreased T-cell expansion in APC-AdFasL treated mice.**

B6+/+ mice were treated with APC-AdFasL or APC-AdControl every 3 days for 5 doses, and then all treated mice were I.V. challenged with AdCMVlacZ (1x10<sup>10</sup> pfu). Three days later, frozen sections of spleen from naive mice (Fig. 7a), 5 control APC treated mice (Fig. 7b), FasL APC treated mice (Fig. 7c) and were stained with anti-CD3 antibody using a standard ABC technique. There was no expansion of CD3<sup>+</sup> T-cells in tolerized mice spleen, whereas mice treated with control APCs resulted in clonal expansion in spleen after challenge.

**Example 20 - APC-AdFasL induces specific tolerance to adenovirus.**

10 To determine if T-cell tolerance induced by Ad/FasL expressing APCs is specific for adenoviral vector rather than a general immune suppression to viral infection, the T-cell response by APC-AdFasL and APC-AdControl tolerized mice to an irrelevant viral infection is measured. B6 +/+ mice are treated with APC-AdFasL as described above for induction of tolerance, and then challenged 15 7 days later with either adenovirus or mouse cytomegalovirus (MCMV). Although there is a reduction of T-cell response to adenoviral vector, the T-cell response to MCMV is not impaired as demonstrated by the comparable levels of IL-2 produced by the T-cells from both control and FasL APC treated mice (Fig 8).

20 **Example 21 - Fas ligand expressing adenovirus (Ad/FasL- $\beta$ Gal) provides both systemic immune tolerance to Ad transfected APCs and confers privilege on cells that are transfected with the Ad/FasL- $\beta$ Gal.**

APCs transfected with Fas ligand induce specific apoptosis and specific T-cell tolerance to antigens both *in vitro* and *in vivo*. This is observed using a macrophage cell line derived from Fas-deficient C57BL/6(B6)-*lpr/lpr* mice that are transiently transfected with Fas ligand, and then injected into mice of a different MHC. In addition, macrophages co-infected with Fas ligand and viral vector are highly efficient presenters of viral vector antigens and Fas ligand. This results in antigen-specific apoptosis of vector-reactive T-cells. Transfection of Fas ligand into a  $\beta$ -islet cell line also confers immune privilege on the host  $\beta$ -islet-reactive T-cells and prevention of diabetes where the vector is adenovirus. These results show that muscle cells infected with Ad and co-transfected with Fas ligand created an immune privileged site in which the adenovirus is not capable of inducing an immune response.

**Example 22 - APCs transfected with Fas ligand induce apoptosis and specific T-cell tolerance to antigens *in vitro* and *in vivo*.**

An APC line derived by short-term culture of peritoneal macrophages from Fas mutant B6-*lpr/lpr* mice does not express Fas, but expressed MHC class II IA<sup>b</sup>, MHC class I H-2D<sup>b</sup> antigens (Fig. 9a, 9b), Mac-1, and Fc- $\gamma$  receptor (data not shown). Significant levels of the B7 costimulatory molecule are expressed on 50% of the cells (Fig. 9c). This cell line is transfected with a eukaryotic expression vector (pcDNAIII) containing the full-length murine Fas ligand and selected using G418. APCs transfected with Fas ligand (APC-FL), but not control vector (APC-CV), exhibit high Fas ligand activity (Fig. 9d). APC-CV cells are capable of presenting alloantigen as the  $\gamma$ -irradiated cells induced a proliferative

responses in co-cultured splenic H-2<sup>k</sup> T-cells (MRL-+/+ or MRL-*lpr/lpr*) (Fig. 9e). APC-FasL cells are capable of presenting alloantigen and induce a proliferative response if the responding T-cells are obtained from MRL-*lpr/lpr* mice, which do not express Fas. However, presentation of antigen by APCs that express Fas 5 ligand to T-cells that express Fas antigen, obtained from MRL-+/+ mice, abrogated the proliferative response. Thus, in the present invention, presentation of antigen by APCs that express Fas ligand induces tolerance of the Fas-positive responding T-cells.

10 **Example 23 - Induction of allogeneic T-cell tolerance by Fas ligand expressing APCs.**

4-wk-old of MRL-+/+ and -lpr/lpr mice are injected i.v. with macrophages (2 x 10<sup>5</sup>) transfected with Fas ligand or control vector every 3 d for 6 times. On d 3 of the final injection, splenic T-cells are isolated from treated mice and cultured under various stimulatory conditions. 5 x 10<sup>5</sup> T-cells are cultured with 15 2 x 10<sup>5</sup>  $\gamma$ -irradiated total spleen cells from B6 +/+ mice (Fig. 10a). 5 x 10<sup>5</sup> T-cells are cultured with 2 x 10<sup>5</sup>  $\gamma$ -irradiated total spleen cells from BALB/c mice (Fig. 10b). 5 x 10<sup>5</sup> T-cells are cultured with 5 mg/ml of anti-CD3 antibody (Fig. 10c). T-cell proliferation is determined by incorporation of [<sup>3</sup>H]-thymidine at 24, 48, 72 and 96 hours.

20 **Example 24 - Antigen-specific clonal deletion of the T-cells induced by Fas ligand expressing APCs in H-2D<sup>b</sup>/HY reactive TCR transgenic mice.**

25 The ability of APCs that express Fas-ligand to mediate clonal deletion of antigen-specific T-cells is directly tested in female, T-cell receptor (TCR)

transgenic, H-2D<sup>b</sup>/HY-reactive mice. In these mice, the majority of peripheral CD8<sup>+</sup> T-cells bear the transgenic TCR and are reactive with the male HY antigen presented in the context of the H-2D<sup>b</sup> antigen. To obtain cells that bear H-2D<sup>b</sup>, HY antigen and high levels of Fas ligand but not Fas, CD4<sup>+</sup>CD8<sup>-</sup> T-cells are 5 isolated from the peripheral lymph nodes of 5-month-old, male, B6-*lpr/lpr* mice. CD4<sup>+</sup>CD8<sup>-</sup> T-cells isolated from 5-month-old, female, B6-*lpr/lpr* mice are used as controls in which the HY antigen is not expressed. The CD4<sup>+</sup>CD8<sup>-</sup> T-cells obtained from both male and female B6-*lpr/lpr* mice expressed high levels of H-2D<sup>b</sup> antigen (Fig. 11a). The Fas ligand activity of the CD4<sup>+</sup>CD8<sup>-</sup> T-cells is high and 10 specific inhibition of this release by soluble Fas-Ig fusion protein (Fig. 11b). Alloantigen-specific T-cell tolerance was analyzed after i.v. injection of  $1 \times 10^6$  CD4<sup>+</sup>CD8<sup>-</sup> T-cells from either male or female mice into 4-wk-old, female, TCR transgenic +/+ or *lpr/lpr* mice. T-cells from female, TCR transgenic +/+ mice treated with Fas ligand <sup>+</sup>HY<sup>+</sup>, male cells exhibited a decreased proliferative 15 response upon stimulation with either H-2D<sup>b</sup>/HY spleen cells or crosslinking with the M33 anti-clonotypic TCR antibody, but not anti-CD3. Fas ligand-positive cells derived from H-2D<sup>b</sup> female mice had no effect on the H-sD<sup>b</sup>/HY reactivity of recipient T-cells in TCR transgenic female mice. Comparable levels of T-cell proliferation were observed in response to stimulation with anti-CD3, M33 20 antibody, or H-2D<sup>b</sup>/HY cells when the TCR transgenic female mice were treated with CD4<sup>+</sup>CD8<sup>-</sup> T-cells of female mice (Fig. 11c). These results indicate that the decreased response requires the presence of the H-2D<sup>b</sup>/HY antigen on the APCs

and is specific for H-2D<sup>b</sup>/HY reactive T-cells as there was a normal response to crosslinking with anti-CD3.

**Example 25 - Tolerance induction due to Fas-mediated deletion of H-2D<sup>b</sup>/HY Reactive CD8<sup>+</sup> T-cells.**

5           Clonal deletion of H-2D<sup>b</sup>/HY cells is examined by analyzing the numbers of H-2D<sup>b</sup>/HY reactive CD8<sup>+</sup> T-cells in the female TCR transgenic mice using the anti-clonotypic mAb M33. Tolerance induction is carried out as described above and the numbers of M33<sup>+</sup>CD8<sup>+</sup> T-cells in the peripheral lymph node (Fig. 12a) and spleen (Fig. 12b) cells are determined. In untreated, female, transgenic +/- and 10 *lpr/lpr* mice, approx. 30% of the PLN cells were M33<sup>+</sup>CD8<sup>+</sup> T-cells and this percentage is not altered by treatment with female H-2D<sup>b</sup> cells lacking HY antigen (Fig. 12a). After tolerance induction in female, TCR transgenic, +/- mice by Fas ligand-positive H-2D<sup>b</sup>/HY cells, however, only 4% of PLN cells are M33<sup>+</sup> and CD8<sup>+</sup>. This depletion of M33<sup>+</sup>CD8<sup>+</sup> T-cells is inhibited significantly by Fas-Ig 15 treatment in that 19% of the cells are M33<sup>+</sup>CD8<sup>+</sup>. Thus, induction of tolerance by Fas ligand expressing APCs is associated with Fas ligand-mediated clonal deletion of antigen-specific T-cells that recognize the antigen presented by the APCs. Time-course analysis of the deletion of M33<sup>+</sup>CD8<sup>+</sup> T-cells in the spleen showed that the depletion commenced as early as 24 h after treatment in the female TCR 20 transgenic +/- mice that received Fas ligand-positive H-2D<sup>b</sup>/HY cells and continued during the 10-d period of the treatment. Fas-Ig effectively inhibited the deletion in the TCR transgenic +/- mice, which further supports the role of Fas ligand expression on the APCs in clonal deletion. Fas expression also is analyzed

in M33<sup>+</sup>CD8<sup>+</sup> PLN T-cells in the female TCR transgenic *lpr/lpr* mice did not express Fas antigen regardless of treatment. Fas expression on M33<sup>+</sup>CD8<sup>+</sup> T-cells expressed low levels of Fas (14%), whereas additional treatment with Fas-Ig led to the majority of M33<sup>+</sup>CD8<sup>+</sup> T-cells are deleted by Fas ligand expressing APCs.

5 **Example 26 - Inhibition of insulitis in NOD mice using a synegeic  $\beta$ -islet cell line that expresses Fas ligand to induce T-cell tolerance.**

NOD mice develop spontaneous insulitis and diabetes due to a T-cell-mediated autoimmune response to self- $\beta$  cells. The syngeneic  $\beta$  cell line, NIT-1, is used as the APC for Fas ligand expression. NIT-1 cells do not express Fas antigen and do not undergo either anti-Fas antibody or Fas ligand mediated apoptosis (data not shown). This cell line is transfected with an expression vector containing Fas ligand mediated apoptosis (data not shown). This cell line is transfected with an expression vector containing Fas ligand (pcDNAIII) as described in Example 9. Fas ligand transfected, but not control, cells expressed functional Fas ligand (Fig. 13a). 6-wk-old, female, NOD mice are injected once with  $5 \times 10^5$  Fas ligand expressing, or control, NIT-1 cells. Seven d later, the splenic T-cells are isolated from treated NOD mice and co-cultured with irradiated NIT-1 cells. There are increased T-cell proliferative and cytotoxic responses in NOD mice treated with control NIT-1 cells (Fig. 13b,c). In contrast, NOD mice treated with Fas ligand expressing NIT-1 cells only exhibit a minimal increase in response compared with the untreated control. 100% of NOD mice that received no treatment or treatment with NIT-1/CV developed insulitis, and 100% of islets

from each individual mouse are involved. In contrast, only 1 of 3 mice receiving NIT-1/FasL developed minor insulitis, with only 10% of islets involved (Fig. 14).

**Example 27 - Inhibition of Insulitis in Nod mice using NIT-1 - AdFasL as a syngenic  $\beta$  islet cell to induce T-cell tolerance to an Ad vector.**

5 The procedure of Example 25 is repeated with the expression vector of Example 14 substituted therein. NIT-1 - Ad control treated mice develop insulitis involving 100% of islet cells of individual mice. NIT-1 - AdFasL treated mice did not develop insulitis.

10 **Example 28 - Transfection with Fas ligand and adenovirus results in high expression of  $\beta$ -Gal in macrophages.**

The polylysine method is used for targeting Fas ligand and Ad to APC via the receptor-mediated endocytosis pathway (49-51, 68, 69). It is important to link Ad to molecular conjugates, and at the same time preserve both the binding and endosome disruption capabilities of the virus. The linkage is accomplished by 15 conjugating a molecular antibody against a foreign epitope on the adenovirus hexon protein to the polylysine-protein complex. For this purpose a chimeric adenovirus containing a foreign epitope in the surface region of its hexon protein is constructed. The loop region of the hexon protein is a useful foreign epitope expression region.

20 **Example 29 - Creation of an immune-privileged site for prolonged expression of the adenovirus gene product using co-expression of FasL and adenovirus in muscle.**

$10^9$  adenovirus is co-injected into mouse muscle tissue with 5  $\mu$ g of purified FasL DNA under the regulation of the CMV promoter (pFasL), or with

identical control plasmid DNA which does not express Fas ligand. FasL production by adenovirus confers a high level of specific immunity to the adenovirus, prevent immune elimination of cells expressing the adenovirus, and result in prolonged expression of the adenovirus gene product. These results are  
5 consistent with previous studies showing that FasL production in muscle cells created an immune privileged site (42).

**Example 30 - Modification of viral tropism to allow high efficiency targeting to macrophages.**

In addition to the *in vitro* infection and tolerance induction by Ad/FasL,  
10 *in vivo* infection by an Ad/FasL virus is operative. A FasL Tg mouse which overexpresses FasL specifically in T-cells without cytotoxicity is used (70). Similar techniques direct Ad/FasL for high transfection of APCs *in vivo* (macrophages) by targeting adenovirus to the macrophage mannose receptor. This is accomplished using a synthetic molecular conjugate consisting of a  
15 mannosylated polylysine protein combined with the adenovirus fiber/knob protein. A mannosylated polylysine has been demonstrated to bind to the macrophage mannose receptor and lead to high efficiency transfection of DNA complexes into islet cells (71, 72). Modification of adenovirus tropism uses the methods detailed in U.S. Provisional Patent Application 60/054,112 for modification of the  
20 adenovirus knob/fiber protein to include a 10 amino acid polypeptide capable of binding E-selectin and targeting adenovirus to inflamed sites in the synovium and also using an anti-adenovirus sFv/IL-2 fusion protein to direct adenovirus tropism to T-cells.

**Example 31 - Production of an adenovirus-infected, Fas ligand expressing macrophage for induction of tolerance to adenovirus.**

The APC line of Example 22 expresses high level of MHC class I and II antigen, B7 and Fas ligand. This macrophage cell line express high levels of H-2D<sup>b</sup> and I-A<sup>b</sup> as well as B7 upon the stimulation with LPS or IFN- $\gamma$ . This cell lines does not express Fas, exhibits low levels of Fas ligand activity, and has been transfected with a CMV promoter/FasL construct to produce a stable transfected macrophage cell line which expresses FasL. This cell line can also be infected with Ad by known techniques to allow expression of adenovirus antigens and gene products.

**Example 32 - Analysis of Tolerance to Ad/Fas Ligand.**

Tolerance to adenovirus will analyzed using a macrophage cell line that stably expresses Fas ligand (APC-FL) such as that of Example 22 and are infected with the adenovirus by intravenous (i.v.) or intranasal (i.n.) injection to induce tolerance. Tolerance is analyzed at d 2, 7, 14, 28, and 56 h after injection of 5 x 15 10<sup>6</sup> Ad-APC-FL. Mice are bled by retro-orbital sinus puncture for analysis of antibody titer to adenovirus.

**Example 33 - Determination of tolerance to Ad.**

Single cell suspensions of spleen and lung are prepared for determination 20 of the proliferative response upon co-culture with normal, irradiated H-2<sup>b</sup> Ad-APC. T-cells tolerance are evaluated by [<sup>3</sup>H]-thymidine incorporation to measure the T-cell proliferative response, BrdU incorporation, and flow cytometric analysis of BrdU-positive T-cells to determine the frequency of proliferative T-cells, and

7AAD three color flow cytometric analysis to determine apoptosis of the T-cells. The level of IL-2 in the culture supernatants is also measured to determine T-cell activation. A similar technique is used to test to determine if cytotoxic CD8<sup>+</sup> T-cells are tolerized or deleted from the spleen *in vivo*. The CD8<sup>+</sup> T-cells are 5 tested for their ability to lyse chromium-labeled Ad-APC. Purified T-cells are isolated as described in reference to Fig. 10. A suitable effector: target (E:T) ratio of CD8<sup>+</sup> T-cells to chromium-labeled, adenovirus-pulsed macrophage target cells is thereby obtained.

**Example 34 - Construction of an adenovirus producing Fas ligand.**

10 First, a full length 1114bp murine Fas ligand cDNA clone is obtained by conventional methods (73-75). Second, this Fas ligand clone is used to produce the Ad/FasL vector (Fig. 16). Third, this clone has undergone recombination with the adenovirus genome in 293 cells. This construct and variations of this construct are used in the present invention. The Fas ligand cDNA clone is introduced into 15 the pΔE1sp1b shuttle vector. To produce recombinant adenovirus, this DNA is co-transfected into weakly Fas<sup>+</sup> 293 cells. A total of 6 transfections are carried out using 3 different transfection methods including: lipofectin, dotap, and the calcium chloride precipitation method. Under all conditions, the majority of the transfected 293 cells undergo apoptosis within 24 h, whereas minimal apoptosis 20 occurs after transfection of 293 cells with the control shuttle vector.

**Example 35 - Production of pΔE1sp1Bloxp/FasL::**

A Fas ligand expressing recombinant adenovirus, denoted as AdLOXP/FasL recombinant virus is shown in Fig. 17. The pΔE1sp1Bloxp/Fas shuttle vector is co-transfected with pJM17 to produce the AdLOXP/FasL. The shuttle vector is co-transfected with pJM17 to produce the AdLOXP/FasL. The 5 AdLOXP/FasL is co-infected with the Ad/CRE recombinant adenovirus. The CRE excises the LOXP sites placing FasL under the control of the CMV promoter resulting in high levels of expression of FasL. As outlined in the detailed description of the invention, AdLOXP/FasL does not induce toxicity in the 293 cells. The AdLOXP/FasL adenovirus is combined with the Ad/CRE recombinant 10 adenovirus. The CRE protein has been well studied and is demonstrated to be able to excise the LOXP sites which in the present invention construct results in the production of FasL under the CMV promoter. This system was first heavily utilized for production of transgenic mice. It has applied by several investigators for adenovirus recombination (73-75). These viruses can be co-infected into any 15 cell, such as macrophages used herein with high efficiency.

**Example 36 - Confirmation that the macrophage cell line transfected with the adenovirus expresses lacZ and Fas ligand.**

Macrophages are transfected with the recombinant adenovirus. *Lac z* expression is confirmed by  $\beta$ -galactosidase staining as described in Example 8. 20 After gene therapy, mice are analyzed at different time courses for expression of the *lacZ* marker gene in the lung and liver. Fas ligand expression is confirmed by ability of the transfected macrophages to induce apoptosis of  $^{51}\text{Cr}$  labeled and Fas sensitive cell line A20 as per Example 5. These experiments are carried out with

and without the presence of a soluble Fas (sFas) capable of neutralizing Fas ligand activity to demonstrate that cytotoxicity is specific for Fas ligand.

**Example 37 - Treatment of a lung disease with AdCF/FasL transfected into APCs.**

5        The CF gene is ligated into the EcoRV site of the Ad shuttle vector of Figure 16 so as to be under the control of the regulatory element. The CF modified vector, Ad Shuttle CF is co-transfected with pJM17 to produce recombinant AdCF. To produce FasL, this is co-infected with the AdLOXP FasL and AxCanCre. These three viruses will be co-administered intra-nasally into the  
10      airways of 6 week old, female bleomycin - IPF mice. On day 7 after the injection, the mice are challenged with AdCF. The mice so treated are tolerant of the CF gene therapy vector 7 days after challenge.

**Example 38 - Treatment of a lung disease with AdPI/FasL transfected into APCs.**

15       The protease inhibitor (PI) gene is ligated into the EcoRV site of the Ad shuttle vector of Figure 16 so as to be under the control of the regulatory element. The PI modified vector, Ad Shuttle PI is co-transfected with pJM17 to produce recombinant AdPI. To produce FasL, this is co-infected with the AdLOXP FasL and AxCanCre. These three viruses will be co-administered intra-nasally into the  
20      airways of 6 week old, female bleomycin - IPF mice. On day 7 after the injection, the mice are challenged with AdPI. The mice so treated are tolerant of the PI gene therapy vector 7 days after challenge.

**Example 39 - Treatment of hemophilia with AdF8/FasL transfected in APCs.**

The factor VIII gene is ligated into the EcoRV site of the pJM 17 vector of Figure 16 so as to be under the control of the regulatory element. The PI modified vector, Ad Shuttle Factor VIII is co-transfected with pJM 17 to produce recombinant Ad Factor VIII. To produce FasL, this is co-infected with the Ad LOXP FasL and AxCanCre. These three viruses will be co-administered intranasally into the airways of 6 week old, female bleomycin - IPF mice. On day 7 after the injection, the mice are challenged with Ad Factor VIII. The mice so treated are tolerant of the Factor VIII gene therapy vector 7 days after challenge.

10 **Example 40 - Determine the expression of Fas ligand and Ad/β-gal *in vivo* at different time points after infection *in vivo* in tolerized and non-tolerized mice.**

Detailed analysis of expression of Fas ligand RNA and protein, viral RNA and protein, and β-gal is carried out at different time point and under different 15 conditions of tolerance induction involves analysis of tissue sections using immunohistochemical staining for Fas, β-Gal. Tissue sections are also analyzed for in-situ expression by RT-PCR and for apoptosis by the tunel method. The phenotype of T-cell and macrophages in lymphoid organs and lung is determined by flow cytometry analysis. Fas ligand expression by single cell suspension is 20 determined by 1) Cr release assay of Fas apoptosis sensitive target cells, 2) frequency analysis by single cell Fas ligand PCR.

20 **Example 41 - Mechanism to abolish Fas expression of Fas apoptosis signaling by the cell that is infected with the Ad/FasL-gene therapy vector.**

To abolish cell surface Fas expression, it is sufficient to prevent Fas apoptosis signaling, since it is well established that Fas expression does not necessarily correlate with Fas apoptosis signaling (76-81). The analysis of Fas-apoptosis signaling and inhibition of this by IL-1 $\beta$  converting enzyme family members and also inhibitors of HCP are useful in testing abolition. This will be accomplished by incorporating both Fas and known inhibitory proteins of Fas apoptosis into modified Ad virus. A specific construct capable of expressing Fas ligand safely and at the same time protect the Fas ligand expressing cell from autocrine-mediated apoptosis includes both FasL and fragments of IL-1 $\beta$  or 5 repeats of the peptide sequence the CPP32/Yama inhibitor DEVD-CHO, the ICE inhibitor YVAD-CHO which inhibit ICE and CPP32 and prevent Fas-mediated apoptosis in different cells, and Crm A, which block the caspase pathway (81). These experiments show the ablation of the endogenous tropism of the adenovirus and the addition novel tropism of the adenovirus to antigen presenting cells. 10 15 Highly efficient ablation of endogenous tropism is important for using the immune modulating strategies proposed of the present invention.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These 20 patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

Adenovirus Vector	Source of Spleen Cells	Immune Response		
		Proliferation	Cytotoxicity	Anti-adenovirus antibody
Adenovirus-Control Vector	B6-+/+	3 <sup>*</sup>	3 <sup>*</sup>	3 <sup>*</sup>
Adenovirus-Control Vector	B6- <i>lpr/lpr</i>	4 <sup>*</sup>	4 <sup>*</sup>	4 <sup>*</sup>
Adenovirus-Fas Ligand	B6-+/+	0	0	0
Adenovirus-Fas Ligand	B6- <i>lpr/lpr</i>	4 <sup>*</sup>	4 <sup>*</sup>	4 <sup>*</sup>

TABLE 1

References

1. Yang Y. et al. *J. of Immunology*. 155(5):2564-70, 1995.
2. Christ M. et al. *Immunology Letters*. 57(1-3):19-25, 1997.
3. Yang Y. et al. *J. of Virology*. 69(4):2004-15, 1995.
4. Gilgenkrantz H. et al. *Human Gene Therapy*. 6(10):1265-74, 1995.
5. Yang Y. et al. *Proceedings of the National Academy of Sciences of the United States of America*. 91(10):4407-11, 1994.
6. Juillard V. et al. *European J. of Immunology*. 25(12):3467-73, 1995.
7. Yang Y. et al. *J. of Virology*. 70(9):6370-7, 1996.
8. Schowalter DB. et al. *Gene Therapy*. 4(8):853-60, 1997.
9. Qin L. et al. *Human Gene Therapy*. 8(11):1365-74, 1997.
10. Guerette B. et al. *Human Gene Therapy*. 7(12):1455-63, 1996.
11. Zsengeller ZK. et al. *Human Gene Therapy*. 8(8):935-41, 1997.
12. Bellgrau D. et al. *Nature* 1995; 377:630-632.
13. French LE. et al. *J Cell Biol.*; 1996:335-343.
14. Lee J. et al. *Endocrinology* 1997; 138:2081-2088.
15. Griffith TS. et al. *Immunity* 1996; 5:7-16.
16. Watanabe-Fukunaga R. et al. *Nature* 1992;356:314-317.
17. Zhou T. et al. *J. Exp Med* 1992; 176:1063-1072.
18. Suda T. et al. *Cell* 75:1169-78, 1993.
19. Wu J. et al. *Proc Natl Acad Sci U S A* 1994; 91:2344-2348.
20. Suda T. et al. *J Immunol*. 154:3806-13, 1995.

21. Cheng J. et al. *J Immunol.* (In press), 1997.
22. Teng MN. et al. *Clin Immunol Immunopath.* 69:215-222, 1993.
23. Marsters SA. et al. *J Biol Chem.* 26:5747-5750, 1992.
24. Gilgenkrantz H. et al. *Human Gene Therapy.* 6:1265-1274, 1995.
- 5 25. Sawchuk SJ. et al. *Human Gene Therapy.* 7:499-506, 1996.
26. Elshami AA. et al. *Ann. Surg.* 222:298-307; 1995.
27. DeMatteo RP. et al. *Ann. Surg.* 222:229-239, 1995.
28. Goldman MH. et al. *Human Gene Therapy.* 6:839-851, 1995.
29. Amalfitano A. et al. *Proc Natl Acad Sci.* 93:3352-3356, 1996.
- 10 30. Zepeda M. et al. *Gene Therapy.* 3(11):973-9, 1996.
31. Ilan Y. et al. *J. of Clinical Investigation.* 99(5):1098-106, 1997.
32. Bennett J. et al. *Human Gene Therapy.* 7(14):1763-9, 1996.
33. Muruve DA. et al. *Transplantation.* 64(3):542-6, 1997.
34. Sigalla J. et al. *Human Gene Therapy.* 8(13):1625-34, 1997.
- 15 35. J. Virol. 72:2483-2490, 1998.
36. J. Biol. Chem. 253:6551.
37. Nagata S. *Science.* 267:1449-56, 1995.
38. Mountz JD. et al. *J. Immunol.* 155:4829-4837, 1995.
39. Wu J. et al. *Proc Natl Acad Sci USA.* 91:2344-2348, 1994.
- 20 40. Zhou T. et al. *Eur J Immunol.* 24:1019-1025, 1994.
41. Watanabe-Fukunaga R. et al. *Nature.* 356:314-317, 1992.
42. Lau HT. et al. *Science.* 273:109-112, 1996.

43. Griffith TS. et al. *Science*. 270:1189-1192, 1995.
44. T. Zhou et al. (submitted)
45. Zhang HG. et al. *J Virol*. 72(3):2483-2490, 1998.
46. Michou AI. et al. *Gene Therapy*. 4(5):473-82, 1997.
- 5 47. Song W. et al. *Human Gene Therapy*. 8(10):1207-17, 1997.
48. Tripathy SK. et al. *Nature Medicine*. 2:545-550, 1996.
49. Michael SI. et al. *J. Biol. Chem*. 268:6866-9, 1993.
50. Gao L. *Human Gene Therapy*. 4:17-24, 1993.
51. Curiel DT. *Progress in Medical Virology*. 40:1-18, 1993.
- 10 52. Cotten M. et al. *PNAS*. 89:6094-8, 1992.
53. Schwarzenberger P. et al. *Blood*. 87:472-8, 1996.
54. Michael SI. et al. *Gene Therapy*. 2:660-8, 1995.
55. Batra RK. et al. *Gene Therapy*. 1:255-60, 1994.
56. Michael SI. et al. *Gene Therapy*. 1:223-32, 1994.
- 15 57. Garver RI Jr. et al. *Gene Therapy*. 1:46-50, 1994.
58. Wu K. et al. *J. Biological Chemistry*. 271:21323-30, 1996.
59. Ferkol T. et al. *PNAS*. 93:101-5, 1996.
60. Jiang W. et al. *Nature*. 375:151-5, 1995.
61. Clarke S. et al. *PNAS*. 93:1434-1438, 1996.
- 20 62. Phi van L. *Biochem. J*. 313:39-44, 1996.
63. Dighe AS. et al. *Immunity*. 3:657-666, 1995.
64. Sawchuk SJ. et al. *Hum Gene Therapy*. 7:499-506, 1996.

65. Mountz JD. et al. *J Immunol* 155:4829-4837, 1995.
66. Young et al. *Anal. Biochem.* 215:24-30, 1993.
67. Zsengeller ZK. et al. *Hum Gene Therapy.* 6:457-467, 1995.
68. Deshane J. et al. *Cancer Gene Therapy.* 3:89-98, 1996.
- 5 69. Deshane J. et al. *J. Clin. Invest.* 96:2980-2989, 1995.
70. Cheng J. et al. *J. Immunol.* (submitted)
71. Ebbinghaus SW. et al. *Gene Therapy.* 3:287-297, 1996.
72. Saldeen J. et al. *Diabetes.* 45:1197-2203, 1996.
73. Choulika A. et al. *J. Virology.* 70:1792-1798, 1996.
- 10 74. Wang P. et al. *Somatic Cell & Molecular Genetics.* 21:429-441, 1995.
75. Sakai K. et al. *Biochem. Biophys. Res. Comm.* 217:393-401, 1995.
76. Su X. et al. *Immunity.* 2:353-362, 1995.
77. Su X. et al. *J. Immunol.* 156:4198-4208, 1996.
78. Zhou T. et al. *J. Exp. Med.* 183:1879-92, 1996.
- 15 79. Mountz JD. et al. *Journal of Clin. Immunol.* 15:1-16, 1995.
80. Tatsuta T. et al. *J. Immunol.* 157:3949-3957, 1996.
81. Hasegawa J. et al. *Cancer Res.* 46:1713-8, 1996.

Various modifications of the present invention, in addition to those shown and described herein, will be apparent to those skilled in the art of the above description. Such modifications are also intended to fall within the scope of the 20 appended claims.

**Claims**

1        1. A method for promoting immunotolerance in a host to a gene  
2        therapy vector, comprising the step of:

3                transfecting a host cell with said vector, such that said vector expresses a  
4        transgene, an antigen and a ligand, wherein expression of said ligand induces  
5        apoptosis in a T-cell raised against said antigen.

1        2. The method of claim 1 further comprising the step of:  
2                exposing said host to a second vector following therapeutic gene  
3        expression, said second vector expressing said antigen and a second ligand  
4        wherein expression of said second ligand induces apoptosis in said T-cell.

1        3. The method of claim 2 wherein said second ligand induces  
2        apoptosis of said T-cell by the same mechanism as said ligand.

1        4. The method of claim 3 wherein said ligand interacts with a death  
2        domain region molecule DRX of said T-cell, wherein X is selected from the group  
3        consisting of 3, 4, and 5.

1        5. The method of claim 1 wherein transfecting said host cell occurs  
2        *in vitro*.

1           6.     The method of claim 1 wherein transfecting said host cell occurs  
2     *in vivo*.

1           7.     The method of claim 6 wherein transfecting said host cell occurs  
2     by an intra-nasal pathway.

1           8.     The method of claim 6 wherein transfecting said host cell occurs  
2     by an intravenous pathway.

1           9.     The method of claim 1 wherein said vector is a recombinant  
2     adenovirus.

1           10.    The method of claim 1 wherein said vector is a recombinant adeno-  
2     associated virus.

1           11.    The method of claim 1 wherein said vector is a recombinant herpes  
2     virus.

1           12.    The method of claim 1 wherein said vector is selected from the  
2     group consisting of: adenovirus, adeno-associated virus and herpes virus.

1           13. The method of claim 12 wherein said vector is replication  
2           defective.

1           14. The method of claim 12 wherein said vector encodes only  
2           nonpathogenic polypeptides.

1           15. The method of claim 1 wherein said antigen is a polypeptide  
2           encoded for by a vector associated gene.

1           16. A method for creating an immune privileged site in a tissue of an  
2           organism, said method comprising the steps of:

3            providing a gene therapy vector encoding and capable of expressing a  
4           ligand, a transgene and an antigen; and  
5            infecting cells of said tissue with said vector, whereby expression of the  
6           ligand in said tissue induces apoptosis of T-cells raised against said antigen so as  
7           to confer specific immunity to infected cells.

1           17. The method of claim 16 further comprising the step of: reinfecting  
2           said tissue with said vector so as to prolong expression of said therapeutic gene.

1           18. The method of claim 16 wherein said transgene is selected from the  
2           group consisting of CFTR, Factor 8, protease inhibitor and insulin.

1           19. The method of claim 16 wherein said ligand is Fas ligand.

1           20. The method of claim 16 wherein said vector is selected from the  
2       group consisting of Fas ligand, Fas2 ligand, Granzyme B, porferin and an antibody  
3       capable of crosslinking apoptosis molecules, said antibody selected from the group  
4       consisting of anti-Fas, anti-TNFR1, anti-DR3, anti-DR4, and anti-DR5.

1           21. The method of claim 16 wherein said vector is a recombinant  
2       adenovirus.

1           22. The method of claim 16 wherein said vector is selected from the  
2       group consisting of: adenovirus, adeno-associated virus and herpes virus.

1           23. The method of claim 22 wherein said vector is replication  
2       defective.

1           24. The method of claim 22 wherein said vector encodes only  
2       nonpathogenic polypeptides.

1           25. A gene therapy viral vector comprising:  
2       a transgene;

3                   an apoptosis ligand gene; and  
4                   a gene expression control means for directing product synthesis of said  
5                   transgene and said ligand gene.

1                   26.       The vector of claim 25 wherein said vector is a recombinant  
2                   adenovirus.

1                   27.       The vector of claim 25 wherein said vector is a recombinant adeno-  
2                   associated virus.

1                   28.       The vector of claim 25 wherein said vector is a recombinant herpes  
2                   virus.

1                   29.       The vector of claim 25 wherein said vector is selected from a group  
2                   consisting of: adenovirus, adeno-associated virus and herpes virus.

1                   30.       The vector of claim 29 wherein said vector is replication defective.

1                   31.       The vector of claim 25 further comprising only nonpathogenic viral  
2                   vector genes.

1           32.    The vector of claim 25 wherein said apoptosis ligand gene codes  
2    for a ligand selected from the group consisting of: Fas ligand, Fas ligand 2,  
3    Granzyme B, porferin, and an antibody capable of crosslinking apoptosis inducing  
4    molecules.

1           33.    The vector of claim 32 wherein said apoptosis inducing molecules  
2    are selected from the group consisting of: anti-Fas, anti-TNFR1, anti-DR3, anti-  
3    DR4 and anti-DR5.

1           34.    The vector of claim 25 wherein said apoptosis ligand gene codes  
2    for multimers of an apoptosis inducing ligand.

1           35.    The vector of claim 25 wherein said apoptosis ligand gene codes  
2    for an apoptosis inducing functional equivalent of said apoptosis inducing ligand.

1           36.    The vector of claim 35 wherein said functional equivalent is  
2    selected from the group consisting of: a fragment, a truncant, a mutant and a  
3    multimer.

1           37.    The vector of claim 25 wherein said gene expression control means  
2    comprises a promoter, an open reading frame and a signal sequence.

1           38.    The vector of claim 37 further comprising an enhancer.

1           39.    Use of the vector of claim 25 for a gene therapy application.

1           40.    The use of claim 39 wherein the gene therapy application is  
2           correction of a gene defect of a target tissue cell.

1           41.    The use of claim 40 wherein said target tissue cell is selected from  
2           the group consisting of: erythrocytes, bone marrow, lung, pancreas, heart, and  
3           liver.

1           42.    A gene therapy viral vector comprising:  
2           a transgene;  
3           a viral vector gene that is expressed as an antigen on an infected host cell;  
4           a functional equivalent of a Fas ligand gene; and  
5           a gene expression control means for directing product synthesis of said  
6           transgene and said Fas ligand gene.

1           43.    The vector of claim 42 wherein said gene expression control means  
2           comprises a promoter, an open reading frame and a signal sequence.

1           44.    The vector of claim 43 further comprising an enhancer.

1           45.    The vector of claim 44 wherein said enhancer is a viral enhancer.

1           46.    The vector of claim 42 wherein said vector is selected from the  
2    group consisting of: adenovirus, adeno-associated virus and herpes virus.

1           47.    The vector of claim 42 wherein said vector is replication defective.

1           48.    The vector of claim 42 further comprising only nonpathogenic viral  
2    vector genes.

## AMENDED CLAIMS

[ received by the International Bureau on 8 October 1998 (8.10.98);  
original claims 1,16,25 and 42 amended;  
remaining claims unchanged (4 pages)]

1           1.    A method for promoting immunotolerance in a host to a gene  
2    therapy vector, comprising the step of:  
3           transfected a host cell with said vector, such that said vector expresses a  
4    transgene, an antigen and a ligand, wherein expression of said ligand induces  
5    apoptosis in a T-cell raised against said antigen in the host.

1           2.    The method of claim 1 further comprising the step of:  
2           exposing said host to a second vector following therapeutic gene  
3    expression, said second vector expressing said antigen and a second ligand  
4    wherein expression of said second ligand induces apoptosis in said T-cell.

1           3.    The method of claim 2 wherein said second ligand induces  
2    apoptosis of said T-cell by the same mechanism as said ligand.

1           4.    The method of claim 3 wherein said ligand interacts with a death  
2    domain region molecule DRX of said T-cell, wherein X is selected from the group  
3    consisting of 3, 4, and 5.

1           5.    The method of claim 1 wherein transfecting said host cell occurs  
2    *in vitro*.

1           6.    The method of claim 1 wherein transfecting said host cell occurs  
2    *in vivo*.

1           15. The method of claim 1 wherein said antigen is a polypeptide  
2        encoded for by a vector associated gene.

1           16. A method for creating an immune privileged site in a tissue of an  
2        organism, said method comprising the steps of:

3           providing a gene therapy vector encoding and capable of expressing a  
4        ligand, a transgene and an antigen in the tissue of the organism; and  
5           infecting cells of said tissue with said vector, whereby expression of the  
6        ligand in said tissue induces apoptosis of T-cells raised against said antigen so as  
7        to confer specific immunity to infected cells.

1           17. The method of claim 16 further comprising the step of: reinfecting  
2        said tissue with said vector so as to prolong expression of said therapeutic gene.

1           18. The method of claim 16 wherein said transgene is selected from the  
2        group consisting of CFTR, Factor 8, protease inhibitor and insulin.

1           19. The method of claim 16 wherein said ligand is Fas ligand.

1           20. The method of claim 16 wherein said vector is selected from the  
2        group consisting of Fas ligand, Fas2 ligand, Granzyme B, porferin and an antibody  
3        capable of crosslinking apoptosis molecules, said antibody selected from the group  
4        consisting of anti-Fas, anti-TNFR1, anti-DR3, anti-DR4, and anti-DR5.

1           21. The method of claim 16 wherein said vector is a recombinant  
2       adenovirus.

1           22. The method of claim 16 wherein said vector is selected from the  
2       group consisting of: adenovirus, adeno-associated virus and herpes virus.

1           23. The method of claim 22 wherein said vector is replication  
2       defective.

1           24. The method of claim 22 wherein said vector encodes only  
2       nonpathogenic polypeptides.

1           25. A gene therapy viral vector comprising:  
2       a transgene;  
3       an apoptosis ligand gene; and  
4       a gene expression control means for directing product synthesis of said  
5       transgene and said ligand gene in a host.

1           26. The vector of claim 25 wherein said vector is a recombinant  
2       adenovirus.

1           27. The vector of claim 25 wherein said vector is a recombinant adeno-  
2       associated virus.

4                   a functional equivalent of a Fas ligand gene; and  
5                   a gene expression control means for directing product synthesis of said  
6                   transgene and said Fas ligand gene in a host.

1                  43.    The vector of claim 42 wherein said gene expression control means  
2                   comprises a promoter, an open reading frame and a signal sequence.

1                  44.    The vector of claim 43 further comprising an enhancer.

1                  45.    The vector of claim 44 wherein said enhancer is a viral enhancer.

1                  46.    The vector of claim 42 wherein said vector is selected from the  
2                   group consisting of: adenovirus, adeno-associated virus and herpes virus.

1                  47.    The vector of claim 42 wherein said vector is replication defective.

1                  48.    The vector of claim 42 further comprising only nonpathogenic viral  
2                   vector genes.

STATEMENT UNDER ARTICLE 19

Claims 1, 16, 25 and 42 have been amended.

Claims 1, 25 and 42 have been amended to include "in a host" within the body of each claim. Claim 16 has been amended to positively recite in the body of the claim the limitation that the vector contents be capable of expression "in the tissue of the organism." Claims 1, 16, 25 and 42 were held to not involve an inventive step over documents including Muruve, D.A. et al. and Judge, T.A. et al. These claims have been amended to positively recite that the present invention provides immunotolerance to transfected host cells. In contrast, Muruve et al. in overview summary recognizes that adCMV-FasL is ineffective in a transplant setting. The present invention has overcome this limitation of Muruve et al.

Judge et al. disclose a replication defective adenoviral construct containing a full length murine Fas ligand cDNA. Cell lines expressing the Fas ligand were shown to induce apoptosis in Fas sensitive targets. The present invention of amended claims 1, 16, 25 and 42 is operative within a host organism and further includes the introduction of a transgene to a host cell.

It is desired to note that the claimed subject matter is novel and can be shown to comprise an inventive step, evidence of which Applicant reserves the right to make of record in due course of prosecution.

The above amendment does not go beyond the disclosure in the international application as filed.




Fig 1.

2/17






Fig 2.



F1 3




F<sub>1</sub> 4

## No T cell tolerance induction by APC-AdFasL in Ipr/Ipr Mice

**A**

In vivo tolerance induction with APC-AdControl APC-AdFasL

**B**

In vivo tolerance induction with APC-AdControl APC-AdFasL




Fig 5





Fig 6.

## In vivo tolerance induction with APC-AdControl



E 7

8/17




Fig 8.

9/17




Fig 9.

10/17




Fig 10

11/17




Fig 11

12/17





Fig 12



F, J 13




Fig. 14

## rAdCMVLuc/pcDNA3FasL




Fig 15




Fig. 16

17/17




Fig 17

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/10381

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 48/00; C12N 15/63  
 US CL : 424/93.1; 435/320.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1; 435/320.1; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MURAVE, D.A. et al. Adenovirus-Mediated Expression of Fas Ligand Induces Hepatic Apoptosis after Systemic Administration and Apoptosis of Ex Vivo-Infected Pancreatic Islet Allografts and Isografts. Human Gene Therapy. 20 May 1997. Vol. 8. pages 955-963, especially page 956.	1 - 3 , 5 , 6 , 8 - 32,35,37-48
Y	ROSENFIELD, M.A. et al. In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium. Cell, 10 January 1992. Vol. 68. pages 143-155, see pages 143 -144, abstract and Figure 1.	1-6,8,9,12-26,29-48



Further documents are listed in the continuation of Box C.



See patent family annex.

•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 JULY 1998

Date of mailing of the international search report

19 AUG 1998

Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
 ANNE MARIE S. BECKERLEG

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/10381

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,A	CONNELLY, S. et al. In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice. Human Gene Therapy. February 1995. Vol. 6. pages 185-193, see pages 185 and 188, abstract and Figure 1.	1-6,8-48
Y	BELLON, G. et al. Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial. Human Gene Therapy. 01 January 1997. Vol. 8. pages 15-25, see pages 15-17.	1-7,9-48
Y	CONNELLY, S. et al. High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice. Human Gene Therapy. 20 January 1996. Vol. 7. pages 183-195, see pages 183 and 187.	1-6,8,9,12-26,29-48
Y	JUDGE, T.A. et al. Functional analysis of a recombinant Fas Ligand construct. Gastroenterology. April 1997. Vol. 112. No. 4. page A1007, see abstract.	1-3,5-32,35 ,37-48
Y	PENG, L. et al. Construction of Recombinant Adeno-Associated Virus Vector Containing the Rat Preproinsulin II Gene. Journal of Surgical Research. April 1997. Vol. 69. No. 1, pages 193-198, see pages 193-195.	1-8,10,12-20,22-25,27,29-48
A	WAGNER, J.A. et al. Toward Cystic Fibrosis Gene Therapy. Annu. Rev. Med. 1997. Vol. 48, pages 203-216.	1-48
Y,P	SATA, M. et al. Fas Ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. USA. February 1998. Vol. 95, pages 1213-1217, especially page 1213.	1-3,5-32,35,37-48
Y,P	ZHANG, H. et al. Application of a Fas Ligand Encoding a Recombinant Adenovirus Vector for Prolongation of Transgene Expression. Journal of Virology. March 1998. vol. 72. No. 3, pages 2483-2490, see entire document.	1-3,5-32,35,37-48
Y	MINETA, T. et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Medicine. September 1995. Vol. 1. No. 9. pages 938-943, see pages 938-939, Figure 1.	11,28
Y	ADREANSKY, S. et al. Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors. Cancer Research. 15 April 1997. Vol. 57. pages 1502-1509, Figure 1.	11,28

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/10381

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 5,658,776 A (FLOTTE et al) 19 August 1997, whole document	1-8,10,12-20,22-25,27,29-48
Y	US 5,585,362 A (WILSON et al) 17 December 1996, whole document.	1-6,8,9,12-26,29-48
Y,P	US 5,670,488 A (GREGORY et al.) 23 September 1997, whole document.	1-6,8,9,12-26,29-48

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US98/10381

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG - Biosis, Medline, Cancerlit, Embase, Scisearch  
search terms: FAS ligand, FASL, adenovir?, adeno-associated virus, aav, herpes, vector?, granzyme B, porferin, FAS2 ligand, CFTR, factor VIII, factor 8, insulin, anti-TNFR, anti-DR3